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Biomedical count data such as the number of seizures for epilepsy patients,
number of new tumors at each visit or the number vomiting after each chemo-radiation
for the cancer patients are common. Often these counts are measured longitudinally
from patients or within clusters in multi-site trials. The Poisson and negative binomial
models may not be adequate when data exhibit over or under-dispersion, respectively.
On the contrary, a variety of dispersion conditions in count data can be captured by
Conway-Maxwell Poisson (CMP) model.
This doctoral dissertation relegates to developing a statistical methodology to
model longitudinal count data distributed as CMP via mixed effect modeling approach. We propose a Bayesian CMP regression model. Specifically, we develop a
regression model with random intercept and slope to capture heterogeneity among
subjects and dependence over time. In addition, a Bayesian generalized additive
mixed effect model based on CMP is proposed by assuming a non-linear shape of
the functional relationship between mean of longitudinal response and covariates.
Case studies demonstrating the usefulness of the proposed methodology by using real
life clinical trial data are also presented. We apply an adaptive variant of Hamiltonian MCMC to carry out Bayesian computation. The Deviance Information Criterion
(DIC), along with other Bayesian model assessment criteria such as (LPML), (WAIC),
(LOO) are used for model comparisons.
ii

Both in simulation studies and real data analysis, we conclude that in terms
of model fitting, CMP models outperform the competing models when data exhibit
dispersion.
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Chapter 1
Introduction
1.1

General Background

Count data is a common phenomenon in biomedical and public health research. Examples include number of hospitalizations of patients, number of physician visits,
number of epileptic seizures, distinct multiple sclerosis lesions, number of tender or
swollen joints of rheumatoid arthritis patients, symptom counts pertinent to a particular therapeutic regime , number of medicines consumed by patients for treatment of
a specific disease, number of dental caries for patients, number of road accidents, and
number of injury or death per road accidents, etc. Sometimes these data are longitudinally measured or clustered among sites such as hospitals or clinics, hence induce
within-patient or within-cluster correlation. The underlying correlation invalidates
the crucial assumption of independence which is a base for many statistical methods.
To make valid inference, one must consider subject- or cluster-specific heterogeneity
by incorporating random effects in the model. Parameter estimates in random effect
models provide subject-specific interpretation (G. Fitzmaurice et al., 2008). Under-or
over-dispersion is another issue to consider in count data models. Inclusion of random
effects in the model accounts for additional variability in the data arise from repeated
1

measures from same subject, and over- or under-dispersion involved in the counting
process (Morris et al., 2017).
The Poisson distribution is commonly used method for count data modeling.
Since Poisson distribution belongs to the exponential family, modeling in the generalized linear model (GLM) framework under the Poisson assumption is simple.
However, the Poisson distribution is not the best choice to deal with over- or underdispersed data as they violate equal mean and variance assumption. The Negative
Binomial model performs well for over-dispersed, but not for under-dispersed data.
Over-dispersion is highly discussed in the literature while under-dispersion in the
data is also common, especially in the case of rare events. Several generalizations of
Poisson models such as generalized Poisson, restricted generalized Poisson have been
suggested in the literature (del Castillo & Pérez-Casany, 2005; Famoye, 1993; Famoye
et al., 2004; Consul & Jain, 1973; Ridout & Besbeas, 2004). However, the downside
of generalized Poisson models is the inability to capture some level of dispersion due
to truncation of the dispersion parameter under certain conditions (Famoye, 1993).
In this case the Conway-Maxwell Poisson (CMP) distribution is the better choice as
it can capture a wide range of dispersion, and belongs to the exponential family for a
non-varying dispersion parameter (Conway & Maxwell, 1962; K. F. Sellers & Shmueli,
2010).

1.2
1.2.1

Literature Review
Chronology of CMP Distribution and its Applications

The CMP distribution was developed by Conway and Maxwell (Conway & Maxwell,
1962). Minka et al. (2003) discussed approximate computational schemes for moments, and maximum likelihood estimates (MLE) of the parameters of CMP distribution. Shmueli et al. (2005) studied the discrete nature of the distribution, probabilistic
2

properties, special cases of CMP, and the parameter estimation techniques (weighted
least square, maximum likelihood, and Bayesian). In addition, they discussed several
extensions of CMP distribution such as zero inflated, zero deflated CMP distributions, and CMP binomial distribution with a hint to extension to CMP multinomial
distribution.
The works, particularly by Shemueli et al.(2005) revived further research on
the CMP distribution during the last decade. Theoretical developments of CMP are
found in literature. For instances, the conjugate analysis of CMP (Kadane et al.,
2006), the explicit and exact expression of the cumulative density function (CDF) of
CMP along with its useful moments (Nadarajah, 2009), properties of CMP and its
generalization of binomial distribution (referred as CMB) (Daly & Gaunt, 2015), a
bi-variate CMP as a generalization of the bivariate count data model (K. F. Sellers et
al., 2016), sum of the CMP and its special cases (K. F. Sellers et al., 2017), asymptotic
expansion for the normalizing constant of the CMP (Gaunt et al., 2019). Sellers et
al. (2012) provides a good review of CMP modeling approaches, their applications,
and proposed a generalized control chart for CMP data.
Literature reveals the earlier applications of CMP as the modeling of the
state dependent service rates (Conway & Maxwell, 1962), word length in linguistics (Wimmer & Altmann, 1996; Wimmer et al., 1994), count data in marketing and
e-Commerce (Boatwright et al., 2003; Borle et al., 2006; Kalyanam et al., 2007; Borle
et al., 2005; Singh et al., 2009), motor vehicle crashes (Lord et al., 2010, 2008), cure
rate models with application to cutaneous melanoma data (Rodrigues et al., 2009),
seizure counts in epileptic patients (K. F. Sellers et al., 2017). Survival data analysis with a Weibull-Conway-Maxwell-Poisson distribution was suggested by Gupta
& Huang (2017). Choo-Wosoba et al. (2018) studied longitudinal fluoride exposure
with dental fluorosis and dental caries .

3

1.2.2

CMP Distribution

Let yi be the count response for subject i, then the probability mass function (PMF)
of the CMP distribution (Conway & Maxwell, 1962) with shape parameter θi and
dispersion parameter φ is given by

P (Yi = yi ) =

where θi > 0, φ ≥ 0, and Z(θi , φ) =

θiyi
,
(yi !)φ Z(θi , φ)
θik
k=0 (k!)φ

P∞

(1.1)

is the normalizing constant for

i = 1, . . . , I.
The dispersion parameter, φ = 1, < 1, > 1 indicate equi-dispersion, overdispersion and under dispersion respectively. Special cases of CMP are Poisson
(φ = 1), Geometric (φ = 0, θi < 1), and Bernoulli (φ → ∞, pi = θi /(1 + θi )), where pi
is the probability of success. There is no simple closed form for linking θi and φ. However, a formulation is given by Ralph Snider mentioned in K. F. Sellers et al. (2012)
as θi = E(Y φ ), where θi is the expected value of power transform counts with power φ.
1/φ

The approximated mean and variance are E(Y ) ≈ θi

1/φ

− (φ − 1)/2φ, V (Y ) ≈ (θi )/φ

respectively. This approximation might not be accurate for φ > 1 or θ1/φ < 10
(Shmueli et al., 2005). When φ is close to 1 then θi approximates the mean. However,
in case of over-dispersion (φ < 1) or under-dispersion(φ > 1), θi deviates substantially
from the mean.

1.2.3

CMP in GLM

K. F. Sellers & Shmueli (2010) proposed a GLM approach by using a logarithmic
link for the shape parameter of CMP distribution. The authors discussed estimation,
prediction, inference, model diagnostics, interpretation, and test of over dispersion
in frequentist approach. Lord et al. (2010) fitted a GLM using dual links for shape
4

and dispersion parameters respectively and compared gamma and Poisson models.
To account for group level dispersion in the data, K. F. Sellers & Shmueli (2013)
developed a generalization of CMP regression model.
Khan & Jowaheer (2013) modeled the shape parameter of CMP distribution to study longitudinal count data. They estimated the parameters using a joint
generalized quasi-likelihood estimating equation (JGQL) and generalized method of
moments (GMM). Choo-Wosoba et al. (2016) studied zero inflated clustered count
data. They used a modified Newton-Raphson method, maximum pseudo-likelihood
(MPL), and generalized estimating equation (GEE) techniques for parameter estimation. K. F. Sellers & Raim (2016) studied a zero-inflated CMP model. Morris
et al. (2017) extended the CMP generalized linear regression model by incorporating
a random intercept for clustered data. They used a logarithmic link for the shape
parameter and indirectly linked it with the mean of the CMP model. This model is implemented both in SAS (PROC NLMIXED) and R (integrate function for numerical
integration for approximation of marginal likelihood, nlminb function for optimization). The COMPoissonReg R-package (K. Sellers et al., 2019) and COUNTREG
procedure in SAS (SAS Institute Inc. 2014) support CMP GLM and its zero inflated
variants. Choo-Wosoba & Datta (2018) studied zero inflated count data distributed
as CMP with cluster specific random effects using Gaussian-Hermite quadrature.
A number of Bayesian approaches to GLM with CMP distributional assumption of count data found in literature. For instance, Guikema & Goffelt (2008)
proposed GLMs by modeling log link of shape and dispersion parameters simultaneously. They also modeled the centrality parameter (by using a transformation of
the shape and dispersion parameter) with a log link in Bayesian setting by using
Gibbs sampler. Chanialidis et al. (2014) proposed a method to estimate normalizing
constant of CMP using retrospective sampling algorithm. Further, Chanialidis et al.
(2018) proposed a rejection sampling approach combined with exchange algorithm
5

that does not require evaluation of normalizing constant. Wu et al. (2013) studied
a Bayesian spatio-temporal Conway–Maxwell Poisson model with dynamic dispersion parameter. Choo-Wosoba et al. (2018) proposed a Bayesian approach of GLM in
presence of many zero counts in the data.

1.2.4

GAM in Count Data

The Generalized additive model (GAM) was first introduced by T. J. Hastie &
Tibshirani (1990). They states that in clinical trials and observational studies the
GAM is useful for two reasons. It helps to prevent from model miss-specification
that may lead to invalid conclusions regarding treatment efficacy. The GAMs also
provide information regarding the relationship between prognostic factors and disease
risk (T. J. Hastie & Tibshirani, 1990).

Ruppert et al. (2003) discussed the GAM

as a generalized nonparametric regression model.The generalized additive models for
the length of stay in hospitals was studied by Herwartz et al. (2016) in Bayesian
setting. They modeled count data by using Poisson, Negative Binomial, zero inflated
variants of Poisson, and Hurdle model by incorporating group-specific random effect.
T. Hastie (2008) developed a R package ‘gam’ to implement GAM. The available
software for dealing with GAM are VGAM (Yee et al., 2020), polspline (Kooperberg,
2015), mgcv (Wood & Wood, 2015), and gamlss (Stasinopoulos et al., 2017).
The distinctive features of allowing flexible predictor effects, interpretability, and availability of ready-to use software have resulted widespread application
of GAMs. However, literature on GAM for count data is limited.

1.3

Gaps in Literature

The CMP is a general distribution that can capture a wide range of dispersion in count
data. Although biomedical research generates count data frequently, the application
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of CMP in the biomedical field is still limited. Morris et al. (2017) used longitudinal
epilepsy data and showed that CMP model fits better than the corresponding Poisson
and Negative Binomial models. They included subject- specific random intercept in
the model and used Akaike Information Criteria (AIC) (Akaikei, 1973) for model
comparisons. To account for more subject or cluster specific heterogeneity in count
data, we may need to fit models with random intercept and slope. However, literature
indicates that such model has not yet been studied in CMP model setting. Besides,
none of the existing packages supports CMP generalized Mixed Effect Model.
A crucial aspect of GAM is to capture the nonlinear relationship between the
link function and continuous covariates. The GAM was studied in literature using
count data including their zero inflated variants (Harezlak et al., 2018). The CMP distributional assumption of count data not yet been considered in GAM framework. In
addition, the available packages to deal with GAM do not support Conway-MaxwellPoisson modeling of count data generated from any of the cross sectional, longitudinal
or clustered type of studies.

1.4

Specific Aims

Dealing with CMP model is complicated. The CMP probability mass function includes a normalizing constant which is an infinite series, and leads to intractable integration or differentiation. The normalizing constant in CMP is being evaluated by (a)
truncation (Morris et al., 2017; Chanialidis et al., 2018) (b) asymptotic approximation (Minka et al., 2003), and (c) by using an MCMC scheme based on retrospective
sampling method (Chanialidis et al., 2014). The difficulty of this evaluation restricts
the wide application of the distribution for complex models, especially, when models includes high-dimensional random effects. Inclusion of random effects, makes the
CMP mixed model more complicated since the random effects are to be integrated
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out during estimation, especially in classical setting. In addition, dealing with flexible
semi-parametric model (e.g. GAM) is also complicated in classical setting for CMP
model.
To avoid these complexities mentioned above, a Bayesian approach will be
helpful. In Bayesian settings, Guikema & Goffelt (2008) used Gibbs Samplers, ChooWosoba & Datta (2018) used Gibbs sampler and Metropolis-Hastings algorithms , and
Chanialidis et al. (2018) used rejection sampling with exchange algorithm. However,
these methods are computationally intensive, and they did not deal with longitudinal
data by including higher order random effects.
We attempt to use No-U-Turn-Samplers (NUTS), an adaptive variant of
Hamiltonian MCMC (HMC) to draw sample from a posterior distribution. Details
of NUTS and notable advantages of using HMC studied elsewhere (Hoffman &
Gelman, 2014). The use of HMC facilitates quicker convergence for high-dimensional
models irrespective of conjugate priors, and produces less auto correlated samples in
comparison to other sampling techniques.

The specific aims are as follows:
• Aim1:
To develop a Bayesian generalized linear mixed effect model (BGLMM) for
longitudinal count data distributed as CMP.
We hypothesize that inclusion of random effects in the CMP model will capture
more subject or cluster specific heterogeneity, and will perform better in terms
of model fit than the corresponding Poisson and negative binomial (NB) mixed
effect models. In addition, the proposed Bayesian model will be more flexible
to incorporate random effects than in models in the frequentist approach.
• Aim2:
To develop a Bayesian generalized additive mixed effect model (BGAMM) for
8

longitudinal data distributed as CMP.
We hypothesize that the fitted BGAMM with the data distributed as CMP
will perform better in terms of model fit than the corresponding Poisson and
negative binomial (NB) additive mixed effect models. We also anticipate that
the proposed Bayesian model will be more flexible to incorporate random effects
than in the models in the frequentist approach.
• Aim3:
CMP mixed effect implementation in STAN language, and to apply the proposed models in real biomedical data analysis.
We will apply these models to real datasets arising from randomized controlled
trials and compare them by using available model assessment tools, and provide
a tutorial on CMP modeling in STAN

Accomplishing these specific aims will allow us to model biomedical longitudinal or
clustered count data with a flexible distribution. We anticipate, the CMP model will
outperform competing count data models in terms of model fitting.
The inclusion of random intercept and slope in the CMP mixed effect model,
fitting a GAM in the context of CMP distribution, and the use of HMC to implement
the models will be the additions to the existing literature to study longitudinal count
data.
In Chapter 2, we develop a generalized linear mixed effect model. Development
of a generalized additive mixed effect model is outlined in Chapter 3. In Chapter 4,
we illustrate an application of the proposed model to real data arising from a clinical
trial. Overall conclusion and Future research directions are mentioned in Chapter 5.
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Chapter 2
Bayesian Generalized Linear Mixed
Effect model for Longitudinal
Count Data Distributed as
Conway-Maxwell Poisson
2.1

Introduction

In this chapter we assume that longitudinal or cluster count data follow ConwayMaxwell Poisson (CMP) distribution. Statistical modeling on count response with
CMP distributional assumption can accommodate a wide spectrum of dispersion in
the data (Conway & Maxwell, 1962). Longitudinal or cluster count data analysis,
by generalized linear mixed effect model, often includes random intercept (or random
intercept and slope) to capture subject or cluster specific heterogeneity in the data.
In such a model, in classical approach, parameter estimation requires maximization
of marginal likelihood by integrating out the random effects. However, the integral with respect to the random effects becomes intractable due to the involvement
10

of an infinite normalizing constant in CMP probability mass function. To override
the intractability, most classical approaches experience difficulties in approximating
the likelihood with Laplacian or quadrature methods (Choo-Wosoba et al., 2018).
Modeling with high-dimensional random effects or/and small sample size, we might
experience a substantial deviation in the shape of the integrand function from that
of the Gaussian density. The standard Laplace approximation may be inaccurate in
such a situation (Ruli et al., 2016). They also noted that in the classical approach,
model fitting via an iterative weighted least squared (IRLS) method encounters a
non-convergence problem when Fisher’s scoring matrix exhibits low rank for a given
diagonal weight matrix, and enhanced complexity leads to over-fitting of the model.
On the contrary, a Bayesian method can handle a mixed effect model by
avoiding the quadrature method or approximations to the likelihood function (ChooWosoba et al., 2018). A Bayesian approach avoids these approximations by applying
iterative MCMC sampling schemes to draw the values of the random effects, and
allows more flexibility to choose a versatile form of random effects design matrix. Inclusion of priors enables addressing the convergence issues, and avoiding over-fitting of
a model (Ruli et al., 2016). With suitable priors, Bayesian methods provide inference
based on posterior summary instead of maximizing the log-likelihood function.
K. F. Sellers & Shmueli (2010) developed the CMP generalized linear model
(GLM). Later on, in the frequentist setting, Morris et al. (2017) extended the GLM
by incorporating subject-specific random intercept for clustered count data with an
arbitrary truncation of normalizing constant. As a further extension, we propose a
Bayesian generalized mixed effect model (BGLMM) for longitudinal count data by
including random intercept and slope which avoids the integrational intractability.
Although the focus of the study is to incorporate random intercept and slope in the
mixed effect model with CMP distributional assumption of the data, we also explore
models with random intercept only in real data analysis.
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Section 2.2 includes the proposed statistical model while Bayesian inference
along with model assessment criteria are presented in Section 2.3. A detailed simulation study and sensitivity analysis are presented in Section 2.4 and Section 2.5
respectively. Application of the model with clinical trials data are illustrated in Section 2.6. Discussion of the study is noted in Section 2.7. The full conditionals noted
in Appendix A.

2.2

The Proposed Model

2.2.1

CMP Regression Model

Let y i = (yi1 , . . . , yini )T be the independent count response vector of subject i for
i = 1, . . . , I and j = 1, . . . , ni , X i = (xi1 , . . . , xini )T be a (ni ×(p+1)) design matrix of
fixed effect covariates, where xTij = (1, xij1 , . . . , xijp ) is a (p + 1) dimensional covariate
vector, Z i = (z i1 , . . . , z ini )T be a (ni × q), (q ≤ (p + 1)) known design matrix, where
z Tij = (1, zij1 , . . . , zij(q−1) ) is a q-dimensional covariate vector, ζ i be a q-dimensional
vector of random effects for the subject i, and β be a (p + 1)-dimensional vector
of regression coefficients. Then, a generalized linear mixed effect model (GLMM) is
defined by

E(y i |β, ζ i ) = g −1 (X i β + Z i ζ i ),

(2.1)

where g −1 (·) is a link function.

Further, let θij be the shape parameter of CMP distribution associated with
a response, yij from subject i at time j. Then, the GLMM for longitudinal count
response (distributed as CMP) is given by
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log(θij ) = xTij β + z Tij ζ i ,

(2.2)

where ζ i ∼ Nq (0, D), D is the covariance matrix for random effects. Let ζ qi = (ζ 0 , ζ 1 )
be the vector of random intercept and random slope, then




2
ρσ0 σ1 
 σ0
D=
,
2
ρσ0 σ1
σ1

where σ02 and σ12 are the variances of intercept and slope, respectively, and ρ is the
correlation between them.

2.2.2

The Likelihood Function

By considering the random effects as the latent variables, the complete data likelihood
can be written in the following form:

L(β, φ, D) =

"n
I
i
Y
Y
i=1

#
f (yij |β, φ, ζi )f (ζi |D) .

(2.3)

j=1

When the response yij distributed as CMP, we can write equation (2.3) as
φ 
ni 
I Y
Y
yij
1
T
T
×
× exp xij β + z ij ζ i
L(β, φ, D) =
yij !
i=1 j=1
 T −1 
I
1
Y
−(q/2) exp − 2 ζ i D ζ i
× (2π)
.
1
2
|
D|
i=1

P∞

k=0

exp xTij β + z Tij ζ i
(k!)φ

(2.4)
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k !−1

2.3

Bayesian Inference

The Bayesian model fitting requires specification of prior distributions, generation of
the joint posterior distribution for the parameters of interest, and obtaining MCMC
samples from the posterior distribution by using suitable samplers to avoid complex or
intractable integration. Bayesian computation enables generating posterior summary
and exploring different characteristics of the parameters.

2.3.1

Priors and Posteriors

In order to fit a Bayesian GLMM, we assume that β, D, and φ are independent
apriori. Thus,
π(β, D, φ) = π(β) × π(D) × π(φ).

(2.5)

We further assume that β ∼ Np (β 0 , Σ0 ), φ ∼ LN (µφ , ψ), and D ∼ IW (ϕ, ω). Then
the joint posterior distribution under the proposed model is given by
"
π(β, D, ζ, φ | y) =

ni
I Y
Y

#
f (yij | β, φ, ζi ) × π(β) ×

i=1 j=1

"

I
Y

#
f (ζ i | D) × π(D) × π(φ)

i=1

φ 
ni 
I Y
Y
 yij
1
∝
× exp xTij β + z Tij ζ i
yij !
i=1 j=1
k !−1
P∞
T
T
β
+
z
ζ
exp
x
ij i
ij
k=0
×
φ
(k!)
 h
i


1
T −1
I
exp − 2 (β − β 0 ) Σ0 (β − β 0 )
Y
exp − 21 ζ Ti D −1 ζ i
×
×
1
1
|Σ0 | 2
|D| 2
i=1


1 log φ−µφ 2


exp
−
(
)
(ϕ+q+1)
2
ψ
1
× |D|− 2 exp − Tr(ωD −1 ) ×
.
2
ψφ
(2.6)
In (2.6), we use inverse-Wishart (IW ) distribution for D and log-normal distribution for φ. However, a wide variety of priors can be used with different parameter
specifications such as uniform prior for β, multivariate-t prior for random effects, and
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any distribution with positive support such as half-Cauchy, gamma or uniform for φ,
inverse gamma for variance parameters of the random effects. As discussed in Barnard
et al. (2000), the inverse-Wishart distribution is a natural choice of D due to conjugacy. The alternative choices of priors are scaled inverse-Wishart (O’Malley &
Zaslavsky, 2008), hierarchical half-t prior (A. Huang et al., 2013), restricted Wishart
distribution (Wang et al., 2018), and separation of covariance strategy (Barnard
et al., 2000). However, Alvarez et al. (2014) noted that the IW prior suffers from
the limitations, such as (a) a single degree of freedom parameter ϕ controls uncertainty in all variance parameters and does not allow flexibility to incorporate various
amount of prior knowledge to various variance components (Gelman et al., 2013), (b)
if ϕ > 1, the marginal distribution of variance parameter retains lower density close
to the zero region and causes bias in the posterior estimate of variance (Gelman et
al., 2006), and (c) it imposes dependency between variance and correlation, meaning that larger variances are associated with extreme correlations (near to +1 and
−1) while smaller variances are associated with correlations near to zero (Tokuda et
al., 2011). However, we can also consider distribution of correlation or its variants
as a prior. Alternatively, there is a separation strategy proposed in Barnard et al.
(2000), which treats variance and correlations independently. For example, using the
separation strategy, the covariance matrix D is decomposed as

 

σ0 0  σ0 0 
D=
Ω
,
0 σ1
0 σ1
where Ω is a correlation matrix, and defined as




 1 ρ
Ω=
.
ρ 1
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Lewandowski et al. (2009) suggests the LKJ (Lewandowski, Kurowicka and
Joe) distribution to sample correlation matrix Ω uniformly from a space of positive
definite correlation matrices. Currently, the LKJ distribution is used as a default
option in Stan language (Carpenter et al., 2017).
If Ω ∼ LKJ(η), then the density is given in Lewandowski et al. (2009) as

f (Ω) ∝ det(Ω)(η−1) .

The parameter η controls the shape of the distribution. The value η = 1
indicates the prior is uniform over all valid correlation matrices, η = 2 indicates ρ
retains high concentration at closer to zero region. The extreme correlation become
less plausible as the value of η increases

(McElreath, 2020). The identity matrix

is the modal correlation matrix when η > 1 , and the density has a trough at the
identity matrix when 0 < η < 1 (Stan user’s guide, version 2.18).
The density of Ω under LKJ distribution with different values of the shape
parameter is shown in Figure 2.1.
Instead of directly modeling correlation matrix Ω with LKJ density, Stan language provides an implicit parameterization in terms of Cholesky decomposition. For
η > 0, the Cholesky decomposition of Ω is given by



l11 0  l11 l12 
Ω = LLT = 

,
l12 l22
0 l22
where L is a lower triangular matrix with lmm > 0, for m = 1, 2 and each row Lm
has unit Euclidian length.
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The general form of LKJ density of a M × M lower triangular matrix L is
given as

T (η−1)

h(L|η) ∝ |J | det(LL )

∝

M
Y

M −m+2η−2
lmm
,

(2.7)

m=2

where h(·) is the density of LKJ distribution, |J | is the Jacobian for the transformation
from Ω to L, and η has the similar interpretation as mentioned above. However, η = 1
does not imply that distribution of L is constant while distribution of LLT is constant
for the same (Stan user’s guide, version 2.18). In our analysis we use distribution of
L as a prior.

2.3.2

Bayesian Model Assessment

The commonly available Bayesian model comparison tools are Deviance Information Criteria (DIC) (Spiegelhalter et al., 2002), Watanabe-Akaike Information Criterion (WAIC), popularly known as widely applicable Bayesian information criterion
(Watanabe, 2013), Pareto smoothed importance sampling leave-one-out cross validation (PSIS-LOO) and K-fold-Cross Validation (K-fold CV) (Vehtari et al., 2017).
DIC suffers from problems as it uses point estimation rather than being fully Bayesian
(Plummer, 2008; Van Der Linde, 2005), DIC is not defined for singular models (Vehtari et al., 2017). The WAIC can overcome some pitfalls of DIC, although there
is no theoretical basis why WAIC is unreliable in some situations (Vehtari et al.,
2017). The k-fold CV provides more reliable results when importance sampling LOO
(IS-LOO) fails for a large number of data points (Vehtari et al., 2017). No method
can dominate all others. Therefore, as the Bayesian model assessment criteria, we
attempt to calculate Monte-Carlo version of conditional predictive ordinate (CPO),
and corresponding logarithm of pseudo-marginal likelihood (LPML) as discussed in
(Geisser & Eddy, 1979; Zhang et al., 2017; Gelfand et al., 1992; Chen et al., 2012).
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In addition, we calculate WAIC, Bayesian Leave One Out cross validation (LOO),
and Deviance Information Criteria (DIC) for Bayesian model assessment. Among
the competing models the best model is the one having the largest LPML, while the
lowest values of LOO, WAIC, and DIC indicate the best fit of the model.

2.3.2.1

Conditional Predictive Ordinate (CPO) and Logarithm of
Pseudo-Marginal Likelihood (LPML)

The conditional predictive ordinate (CPO) is calculated based on leave-one-out cross
validation. To define CPO, let us consider, y = (y 1 , . . . , y I )T be the longitudinal
response data. Then, the CPO provides the estimate of probability of observing a
future yi given the observed y (−i) . The vector y (−i) = (y 1 , . . . , y i−1 , y i+1 , . . . , y I )T
denotes all observations deleting the data points for ith subject. It is the posterior
probability of observing the value of yi when the model is fitted to all data except
yi . Higher value of CPO indicates a better fit of the model to yi while a lower value
reveals that yi is an outlier and influential observation. Following Geisser & Eddy
(1979); Chen et al. (2012), with the given notation the CPO for subject i is defined
as

Z
CPOi =


f (y i | Θ)π Θ | y (−i) dΘ.

(2.8)

On simplification, as noted in (Zhang et al., 2017), we can write

−1
1
CPOi =
π(Θ | y)dΘ
f (yi | Θ)


−1
1
= EΘ|y
,
f (yi |Θ)
Z
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(2.9)

where Θ includes (β, φ, and D). Following Chen et al. (2012); Zhang et al. (2017),
the Monte Carlo estimate of the CPO (B is the number of MCMC samples) is given
by
"

B
X
1
di = 1
CPO
B b=1 f (yi |Θ(b) )

#−1
.

(2.10)

Then, the LPML is defined as

LPML =

I
X

d i ).
log(CPO

(2.11)

i=1

2.3.2.2

Leave One-Out-Cross-Validation (LOO)

Following the similar notations in section 2.3.2.1, the leave-one-out predictive density
for a given dataset deleting the ith data point is given as

elpdloo =

I
X

log f (yi |y (−i) ),

(2.12)

i=1

where
Z
f (yi |y (−i) ) =

f (yi |Θ)π(Θ|y (−i) )dΘ.

(2.13)

On simplification, as noted in Vehtari et al. (2017), from MCMC samples, (2.13) can
be approximated as

f (yi |y (−i) ) ≈

B
h1 X

B

b=1

i−1
1
.
f (yi |Θ(b) )

(2.14)

Then, to provide the output on the conventional scale of deviance, we can write

LOO = −2

I
X
i=1

log

B
h1 X

B
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b=1

i−1
1
.
f (yi |Θ(b) )

(2.15)

2.3.2.3

Watanabe–Akaike Information Criterion (WAIC)

The WAIC is an alternative measure to estimating the expected log pointwise predictive density and is defined as

d
c p
elpd
waic = lpd − b
waic ,

(2.16)

c is
where the computed log point-wise predictive density (lpd)

c =
lpd

I
X
i=1

"

B
1 X
1
log
B b=1 f (yi |Θ(b) )

#−1
,

(2.17)

and the estimated effective number of parameters (b
pwaic ) is defined as

b
pwaic =

I
X



Var log f (yi |Θ(b) ) .

(2.18)

i=1

As mentioned in Vehtari et al. (2017), on the conventional scale of deviance or AIC
we can write
I
I
B
oi X


n1 X
h1 X
(b)
f (yi |Θ ) −
Var log f (yi |Θ(b) ) .
log
WAIC = −2
I i=1
B b=1
i=1

2.3.2.4

(2.19)

Deviance Information Criterion (DIC)

The Deviance Information Criteria (DIC) proposed by Spiegelhalter et al. (2002)
is the most widely used method for Bayesian model comparison which includes
goodness-of-fit of the model as well as complexity of the model in terms of effective
number of parameters (pD ). Let y be generated from the probability model f (y|Θ),
R
then the marginal distribution of y, f (y) = Θ f (y|Θ)π(Θ)dΘ, where π(Θ) is the
prior distribution of Θ. The posterior distribution, π(Θ|y) ∝ f (y|Θ)π(Θ). Then,
the DIC is defined as
DIC = ∆(Θ) + pD ,
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(2.20)

where ∆(Θ) = −2 log f (y | Θ), is the deviance function, ∆(Θ) is the posterior mean
of deviance, and pD = ∆(Θ) − ∆(Θ̄) is the effective number of parameters. On
simplification,
DIC = 2∆(Θ) − ∆(Θ̄).

(2.21)

In addition, we monitor convergence of the MCMC chains by observing scale
reduction statistics R̂ that measures the ratio of the average variance of samples
within each chain to the variance of the pooled samples across chains. A value of R̂
closer to 1 indicates that each set of B simulated values is close to the target distribution (Gelman et al., 1992). To monitor the performance of the MCMC samples,
we also observe effective number of sample size (ESS) where the higher ESS is an
indication of the higher number of independent MCMC samples, trace plots visualizing the convergence status of MCMC samples, auto-correlation plots (ACF plots)
where exponential shape is an indication of producing non-autocorrelated samples,
pair plots and density plots illustrating the non-disruption in MCMC samples for the
posterior means of the parameters (some of them are noted in Section 2.6).

2.4

Simulation Study

We perform a simulation study to demonstrate the flexibility and performance of the
CMP mixed effect model with correlated subject-specific random intercept and slope.
The datasets resemble clinical trial type of data where treatment arm consists of 40%
of the subjects. We generate 100 longitudinal datasets each of having n = 100 subjects
with 5 measurements in 5 distinct time points (t = 0, 1, . . . 4) in under-dispersed
(φ = 2.50), over-dispersed (φ = 0.30) and equi-dispersed (φ = 1.00) conditions
respectively. The time tij is then converted as binary variable (0 =baseline or 1=postbaseline). We assume that patient condition improve by 1% during post-baseline
period, as it happens in some clinical trials due to counselling effect irrespective of
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intervention. The only explanatory variable, x ∼ Bernoulli(0.40) mimics a treatment
assignment to 40% of the patients, and we assume a moderate beneficial (5%) effect
of treatment on the subjects. Random effects are generated with the specifications of
ζ0 ∼ N (0, 0.052 ) and ζ1 ∼ N (0, 0.022 ). Correlation, ρ between random intercept and
slope is considered as −0.50. The true values of the regression coefficients β1 =−0.05,
and β2 =−0.01 represent the beneficial effect of treatment and time respectively. We
consider β0 =−0.8. Then the response counts, yij s are generated with the specification,
yij ∼ CM P (θij , φ), where θij = exp (β0 + β1 xij + (β2 + ζ1i )tij + ζ0i ).
In each dispersion condition we applied CMP, negative binomial (NB), and
Poisson model respectively with 5, 000 iterations (50% warm-ups) in each of the 4
chains. We compute Monte-Carlo versions of CPO and LPML, LOO, WAIC, and
DIC along with their respective inter-quartile range (IQR) for the purpose of model
assessments. Posterior mean, standard error (SE), mean squared error (MSE), and
coverage probability (CP%) (in 95% credible interval) are reported in Tables 2.1,
2.2, and 2.3 for three dispersion conditions respectively. We also perform graphical
illustration of subject-wise CPOs from all samples for all dispersion conditions to
observe existence of extreme observations. However, we report here only the graph
for CMP model with under-dispersed data in Figure 2.2, and the rest are reported in
Appendix C.
Table 2.1 presents the results obtained from CMP, NB, and Poisson model
assuming under-dispersed (φ = 2.50) simulated data. The CMP model produces the
posterior mean of dispersion parameter as φ = 2.82 with a MSE=0.48. The result
supports that data are under-dispersed since φ > 1. On the other hand, NB model
produces a negligible value for φ (0.04). However, dispersion parameters in CMP
and NB carry different interpretations. When value of the dispersion parameter in
NB approaches to zero, it indicates there is no over dispersion in the data, and data
distribution approaches to the Poisson distribution. On the other hand, when the
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Table 2.1: Simulation results for under-dispersed data (φ = 2.50)
Model

CMP

NB

Poisson

Param

True

Mean

SE

MSE

CP (%)

LPML

LOO

WAIC

DIC

(IQR)

(IQR)

(IQR)

(IQR)

φ

2.50

2.82

0.61

0.48

91%

−99.93

−199.87

714.39

714.39

β0

−0.80

−0.87

0.18

0.01

94%

(3.45)

(6.90)

(26.45)

(26.67)

β1

−0.05

0.03

0.18

0.04

92%

β2

−0.01

0.01

0.24

0.06

95%

σ0

0.05

0.13

0.05

0.01

100%

σ1

0.02

0.14

0.06

0.02

100%

ρ

−0.50

−0.02

0.02

0.22

100%

φ

-

0.04

0.00

-

-

−101.35

−200.71

713.01

732.27

β0

−0.80

−1.12

0.18

0.13

69%

(3.51)

(7.03)

(26.13)

(26.29)

β1

−0.05

0.02

0.14

0.02

95%

β2

−0.01

0.02

0.19

0.04

97%

σ0

0.05

0.07

0.01

0.00

100%

σ1

0.02

0.08

0.01

0.00

100%

ρ

−0.50

−0.04

0.01

0.43

100%

β0

−0.80

−1.11

0.18

0.13

69%

−100.33

−200.66

729.72

730.95

β1

−0.05

0.02

0.13

0.02

94%

(3.51)

(7.03)

(26.06)

(26.35)

β2

−0.01

0.02

0.19

0.04

96%

σ0

0.05

0.07

0.01

0.00

100%

σ1

0.02

0.07

0.01

0.00

100%

ρ

−0.50

−0.04

0.01

0.21

100%

dispersion parameter in CMP equals to 1, it indicates there is no over dispersion in
the data, and data distribution approaches to the Poisson distribution.
In the case of NB the regression coefficients are β0 =−1.12, β1 = 0.02, β2 = 0.02,
while in the Poisson model the corresponding values are β0 =−1.11, β1 = 0.02, β2 =
0.02. In terms of parameter estimates we experience subtle differences between the
two models. Sellers and Shmueli,(2010) reports that both Poisson and NB produce
almost same regression parameter estimates for under-dispersed count response.
The posterior means of regression coefficient for intercept, treatment, and time
in CMP model are β0 =−0.87, β1 =0.03,and β2 = 0.01. Apparently, it is observed that
there are substantial differences in the parameter estimates between CMP and other
two models. An approximate conversion (β/φ) of the CMP regression parameters
enable a direct comparison among the models, and are almost accurate for larger
count response. The converted values for CMP model β0 /2.5=−0.30, β1 /2.5=0.01,
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and β2 /2.5=0.002 illustrate smaller effect sizes of the respective covariates on the
response than that of produced by other models. However, this comparison may not
be accurate as the under-dispersed simulation set up produces smaller counts in this
case. We observe that MSE for intercept parameter in the CMP model is the lowest
while for other parameters a bit higher than that of other models.
In comparison to the NB and Poisson model, the higher values of the estimates
for standard deviations σ0 = 0.13 and σ1 = 0.14 for random intercept and slope in
CMP model explain higher spread around the population level intercept and slope.
The negative sign in the correlation coefficients ρ between random intercept and slope
across models indicate that subjects having higher initial responses have slower rate
of improvement.
Based on 95% credible interval, the coverage probabilities for all parameters are
higher than 92% in CMP model while the same for both Poisson and NB are higher
than 69%. Both credible interval and highest posterior density (HPD) ( reported in
Appendix B) interval for all parameters from all models are almost coincided which
illustrates the symmetry of posterior means for respective parameters.
Although there exists no remarkable deviations in the values of LPML and
LOO across three models, we observe that CMP model results the highest value
of LPML (−99.93), and NB model results the lowest value of LOO (−200.71) . In
contrast, CMP model results the lowest values of WAIC (714.394), and DIC (714.393)
followed by Poisson model with WAIC (729.72), and DIC (730.95) respectively. It is
observed that CMP model fits the best on the basis of LPML, WAIC, and DIC. On
the other hand, NB model fits the best based on LOO with a negligible difference.
We applied CMP, NB, and Poisson model to simulated over-dispersed (φ =
0.30) data and report the results in Table 2.2. We observe that the posterior mean
of dispersion parameter in CMP model is φ=0.39 with a MSE=0.04, and reveals
the existence of over-dispersion. The negative signs in treatment effect β1 =−0.01
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Table 2.2: Simulation results for Over-dispersed data (φ = 0.30)
Model

Param

True

Mean

SE

MSE

CP (%)

LPML
(IQR)

CMP

NB

Poisson

LOO

WAIC

DIC

(IQR)

(IQR)

(IQR)

φ

0.30

0.39

0.19

0.04

89%

−77.00

−154.69

1039.48

1038.40

β0

−0.80

−0.83

0.19

0.04

88%

(6.28)

(12.55)

(49.44)

(49.85)

β1

−0.05

−0.01

0.10

0.01

97%

β2

−0.01

−0.02

0.16

0.03

91%

σ0

0.05

0.16

0.05

0.01

100%

σ1

0.02

0.17

0.05

0.03

98%

ρ

−0.50

−0.17

0.05

0.11

100%

φ

-

0.45

0.19

-

-

−77.00

−153.95

1040.76

1040.25

β0

−0.80

−0.58

0.18

0.08

72%

(6.11)

(12.38)

(47.78)

(47.92)

β1

−0.05

−0.01

0.13

0.02

96%

β2

−0.01

−0.02

0.20

0.04

90%

σ0

0.05

0.22

0.03

0.03

99%

σ1

0.02

0.24

0.07

0.05

95%

ρ

−0.50

−0.18

0.06

0.11

100%

β0

−0.80

−0.64

0.20

0.06

85%

−75.00

−150.29

1055.56

1045.37

β1

−0.05

−0.01

0.13

0.02

97%

(5.49)

(10.98)

(50.56)

(47.02)

β2

−0.01

0.00

0.21

0.04

89%

σ0

0.05

0.38

0.16

0.13

76%

σ1

0.02

0.41

0.17

0.18

44%

ρ

−0.50

−0.33

0.17

0.06

100%

and time effect β2 =−0.02 and the corresponding transformed values (β1 /0.39=−0.03
) and (β2 /0.39=−0.03) produced by CMP model indicate positive impacts of both
treatment and time on count response, and they are markedly different than that
of Poisson and NB model. The MSEs for β1 and β2 in CMP models are 0.01 and
0.03 respectively, also smaller than that of other models. The MSEs for σ0 and σ1 in
CMP model are much smaller than NB and Poisson models respectively. Coverage
probabilities in CMP model for all parameters are above 88% while the same for NB
model are more than 72% and for Poisson more than 44%. We observe that Poisson
model produces the highest value of LPML (−75.00) among the three models. On the
contrary, the lowest values of LOO (−154.69), WAIC (1039.48), and DIC (1038.40)
illustrate the best fit of CMP model among others. In addition, NB model fits better
than the Poisson model in case of over-dispersed data which is expected.
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Table 2.3: Simulation results for Equi-dispersed data (φ = 1.0)
Model

Param

CMP

NB

Poisson

True

Mean

SE

MSE

CP (%)

LPML

LOO

WAIC

DIC

(IQR)

(IQR)

(IQR)

(IQR)

φ

1.00

1.23

0.30

0.14

84%

90.10

−180.25

859.80

859.48

β0

−0.80

−0.81

0.16

0.03

96%

(4.92)

(9.82)

(42.60)

(43.12)

β1

−0.05

0.00

0.15

0.02

94%

β2

−0.01

−0.04

0.18

0.03

98%

σ0

0.05

0.23

0.07

0.04

100%

σ1

0.02

0.25

0.08

0.05

88%

ρ

−0.50

−0.18

0.05

0.11

100%

φ

-

0.07

0.03

-

-

90.50

−180.93

859.12

859.88

β0

−0.80

−0.85

0.15

0.02

96%

(4.91)

(9.81)

(42.51)

(43.30)

β1

−0.05

−0.00

0.14

0.02

94%

β2

−0.01

−0.05

0.16

0.03

98%

σ0

0.06

0.18

0.04

0.02

100%

σ1

0.02

0.20

0.04

0.04

100%

ρ

−0.50

−0.16

0.03

0.12

100%

β0

−0.80

−0.85

0.15

0.02

96%

90.30

−180.66

858.73

859.10

β1

−0.05

−0.00

0.14

0.02

94%

(4.78)

(9.45)

(41.65)

(42.97)

β2

−0.01

−0.05

0.16

0.03

98%

σ0

0.05

0.19

0.05

0.02

100%

σ1

0.02

0.21

0.05

0.03

98%

ρ

−0.50

−0.16

0.03

0.11

100%

We report simulation results from equi-dispersed data in Table 2.3. We notice
that Poisson model retains the lowest WAIC (858.73) and DIC (859.10) values than
that of other models indicating the best fit while the second alternative is CMP model
based on DIC. On the contrary, both LPML and LOO values illustrate that NB model
fits better than others. However, differences in LPML and LOO across models are
minuscule. MSE for parameters in Poisson model are smaller or at least equivalent
to other models.
Both WAIC and DIC provide consistent conclusions regarding model fit for all
models while both LPML and LOO provides contradictory conclusions.
Figure 2.2 presents boxplots for subject-wise CPO from 100 under-dispersed
simulated samples. We produce similar graph for over- and equi-dispersed data cases
too (reported in Appendix C). Extreme low values of CPO indicate that the respective
data points are outliers. We observe that out of 100 subjects very few retain extreme
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low CPO values for some samples, which indicate that simulation data are more or
less homogeneous.

2.5

Sensitivity Analysis

We perform a sensitivity analysis for the over-dispersed (φ = 0.30) simulated data by
changing hyper parameters in priors as well as prior distributions to investigate their
influences on posteriors means. The results are presented in Table 2.4 and Table 2.5
respectively. We apply CMP model with correlated random intercept and slope with
the following prior specifications βk ∼ N (0, 10000), φ ∼ LN (0, 15), ζ ∼ N (0, σζ2 ), σζ2 ∼
U (0, ∞), L ∼ LKJ(2). Then we change parameter values in five scenarios for each
of the cases from O1 to O4 (see Table 2.4).
In Table 2.4 we observe that posterior means of the regression parameters are
almost identical for all scenarios (S1 to S5 ) for the cases O1 to O4 . In O4 , we notice
that for different choices of parameter η in LKJ distribution the posterior means of
the parameters σ0 , σ1 , and ρ vary remarkably. In particular, we experience notable
deviations in these parameter values when η moves downward from 1.5 to 0.5, meaning
that when density moves towards uniformity.
Table 2.5 illustrates the effect of prior changes on posterior means. In scenarios S1 to S5 , we consider defuse normal prior for regression co-efficients, gamma or
half-Cauchy prior for φ in place of log normal, and inverse gamma or half-Cauchy
for σ02 and σ12 instead of uniform, and experience no remarkable changes in regression co-efficients. However, we notice substantial changes in standard deviations and
correlation parameters across scenarios. It is evident that regression estimates are
not much sensitive to the priors while estimates for σ0 , σ1 , φ, and ρ are remarkably
sensitive.
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Table 2.4: Posterior summary for over-dispersed data with different choices of hyperparameters in priors
Posterior means
Scenarios
βˆ0

βˆ1

βˆ2

σˆ0

σˆ1

ρ̂

φ̂

(95%HPD)

(95%HPD)

(95%HPD)

(95%HPD)

(95%HPD)

(95%HPD)

(95%HPD)

O1 :Parameters for βk vary
S1 : βk ∼ N (0, 10000)

S2 : βk ∼ N (0, 100)

S3 : βk ∼ N (0, 50)

S4 : βk ∼ N (0, 3)

S5 : βk ∼ N (0, 2)

−0.71

0.01

−0.16

0.29

0.33

−0.22

0.40

(−1.01, −0.42)

(−0.22, 0.22)

(−0.43, 0.10)

(0.00, 0.79)

(0.00, 0.92)

(−0.98, 0.62)

(0.01, 0.70)

−0.71

0.01

−0.16

0.26

0.31

−0.19

0.39

(−1.01, −0.42)

(−0.22, 0.22)

(−0.41, 0.08)

(0.00, 0.65)

(0.00, 0.79)

(−0.94, 0.64)

(0.01, 0.68)

−0.70

0.01

−0.16

0.28

0.33

−0.20

0.40

(−1.01, −0.42)

(−0.22, 0.22)

(−0.41, 0.09)

(0.00, 1.72)

(0.00, 0.86)

(−0.94, 0.67)

(0.01, 0.70)

−0.71

0.01

−0.16

0.28

0.34

−0.22

0.40

(−0.99, −0.42)

(−0.22, 0.22)

(−0.42, 0.08)

(0.00, 0.75)

(0.00, 0.89)

(−0.94, 0.67)

(0.01, 0.70)

−0.70

0.00

−0.17

0.29

0.35

−0.21

0.41

(−1.00, −0.41)

(−0.21, 0.22)

(−0.41, 0.10)

(0.00, 0.78)

(0.00, 0.97)

(−0.97, 0.65)

(0.06, 0.75)

O2 :Parameters for φ vary
S1 : φ ∼ LN (0, 100)

S2 : φ ∼ LN (0, 30)

S3 : φ ∼ LN (0, 10)

S4 : φ ∼ LN (0, 3)

S5 : φ ∼ LN (0, 0.5)

−0.70

0.01

−0.16

0.27

0.33

−0.20

0.40

(−1.00, −0.42)

(−0.21, 0.23)

(−0.41, 0.10)

(0.00, 0.70)

(0.00, 0.84)

(−0.94, 0.66)

(0.02, 0.71)

−0.71

0.01

−0.16

0.29

0.34

−0.21

0.40

(−0.99, −0.40)

(−0.21, 0.23)

(−0.41, 0.11)

(0.00, 0.77)

(0.00, 0.91)

(−0.95, 0.66)

(0.01, 0.70)

−0.70

0.01

−0.17

0.26

0.32

−0.20

0.40

(−0.99, −0.40)

(−0.21, 0.23)

(−0.40, 0.10)

(0.00, 0.69)

(0.00, 0.81)

(−0.97, 0.64)

(0.02, 0.71)

−0.70

0.01

−0.16

0.27

0.33

−0.21

0.41

(−1.00, −0.42)

(−0.21, 0.22)

(−0.42, 0.10)

(0.01, 0.96)

(0.01, 1.14)

(−0.94, 0.73)

(0.07, 0.75)

−0.63

−0.01

−0.18

0.34

0.40

−0.24

0.56

(−0.92, −0.34)

(−0.22, 0.23)

(−0.43, 0.09)

(0.00, 0.85)

(0.00, 1.00)

(−0.98, 0.61)

(0.31, 0.83)

2
O3 :Parameters for σζ
vary
2
S1 : σζ
∼ U (0, 1000)

2
S2 : σζ
∼ U (0, 30)

2
∼ U (0, 10)
S3 : σζ

2
S4 : σζ
∼ U (0, 3)

2
S5 : σζ
∼ U (0, 1)

−0.70

0.01

−0.16

0.30

0.36

-0.23

0.41

(−1.00, −0.40)

(−0.21, 0.23)

(−0.42, 0.09)

(0.00, 0.82)

(0.00, 0.98)

(−0.97, 0.61)

(0.02, 0.74)

−0.70

0.01

−0.16

0.31

0.36

-0.22

0.41

(−1.00, −0.41)

(−0.22, 0.22)

(−0.41, 0.09)

(0.00, 0.98)

(0.00, 1.10)

(−0.97, 0.63)

(0.01, 0.75)

−0.71

0.01

−0.16

0.26

0.32

-0.20

0.39

(−1.01, −0.41)

(−0.21, 0.23)

(−0.40, 0.10)

(0.00, 0.68)

(0.00, 0.82)

(−0.99, 0.64)

(0.01, 0.68)

−0.71

−0.01

−0.16

0.29

0.31

-0.22

0.41

(−1.00, −0.42)

(−0.21, 0.23)

(−0.42, 0.11)

(0.00, 0.81)

(0.00, 0.98)

(−0.99, 0.63)

(0.01, 0.72)

−0.71

0.01

−0.16

0.25

0.30

-0.19

0.39

(−1.01, −0.43)

(−0.22, 0.23)

(−0.42, 0.08)

(0.00, 0.63)

(0.00, 0.73)

(−0.96, 0.64)

(0.01, 0.68

O4 :Parameters for L vary
S1 : L ∼ LKJ(5)

S2 : L ∼ LKJ(3)

S3 : L ∼ LKJ(1.5)

S4 : L ∼ LKJ(1)

S5 : L ∼ LKJ(0.5)

−0.70

0.01

−0.17

0.23

0.28

−0.08

0.40

(−0.99, −0.41)

(−0.22, 0.22)

(−0.42, 0.07)

(0.00, 0.55)

(0.00, 0.67)

(−0.70, 0.50)

(0.01, 0.68)

−0.70

0.01

−0.17

0.25

0.30

−0.13

0.39

(−1.01, −0.41)

(−0.21, 0.22)

(−0.42, 0.09)

(0.00, 0.62)

(0.00, 0.62)

(−0.84, 0.62)

(0.05, 0.72)

−0.71

0.01

−0.16

0.31

0.38

−0.27

0.41

(−1.01, −0.42)

(−0.21, 0.23)

(−0.42, 0.09)

(0.00, 0.85)

(0.00, 1.02)

(−1.00, 0.68)

(0.01, 0.73)

−0.72

0.01

−0.14

0.36

0.43

−0.38

0.41

(−1.01, −0.42)

(−0.21, 0.21)

(−0.39, 0.13)

(0.00, 0.98)

(0.00, 1.19)

(−1.00, 0.75)

(0.04, 0.73)

−0.73

0.01

−0.11

0.55

0.67

−0.61

0.45

(−1.06, −0.44)

(−0.21, 0.24)

(−0.41, 0.20)

(0.00, 1.53)

(0.00, 1.80)

(−1.00, 0.83)

(0.01, 1.02)
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To compare the regression parameter estimates across scenarios, we construct
forest plots, illustrated in Figures 2.3 to 2.7, for 95% HPD intervals and their respective mean values (solid circles) obtained from Table 2.4 and Table 2.5. All the
figures evidence that posterior means for regression parameters are quite robust across
scenarios.

2.6

Application to Randomized Controlled Clinical trials Data

To demonstrate the applicability of our proposed model we use data from two distinct
clinical trials. The first example involves data from placebo-controlled clinical trial
of epilepsy patients, and the second example relates to multi-vitamin supplement in
HIV patients. We report a short description for each dataset along with corresponding
analysis results.

2.6.1

Analysis of Epilepsy data

We fit models with random effects on Epilepsy data discussed in Thall & Vail (1990).
The dataset consists of the number of seizures for 59 patients suffering from epilepsy,
31 of them are assigned to the progabide group, the treatment arm, and the rest in
the placebo group. Seizure rates are longitudinally measured in an initial eight weeks
before baseline and then in every two weeks in four consecutive treatment periods.
The mean and variance of the seizure rate is 12.85 and 349.17 respectively, potentially an indication of over-dispersion in the data. Figure 2.8 presents the individual
profile of seizure rates for selected subjects from placebo and progabide group. The
first measurement at zero is the number of seizures in eight weeks intervals before
randomization and the rests are in every two weeks. We illustrate the treatment armwise profiles in Figure 2.9, and notice that one subject in progabide group retains
29

30

2
2
∼ Cauchy(0, 10), L ∼ LKJ(2)
ζ ∼ N (0, σζ
), σζ

S5 : βk ∼ N (0, 10000), φ ∼ Cauchy(0, 10),

2
2
ζ ∼ N (0, σζ
), σζ
∼ IG(2, 2), L ∼ LKJ(2)

S4 : βk ∼ N (0, 10000), φ ∼ Cauchy(0, 10),

2
2
ζ ∼ N (0, σζ
), σζ
∼ Cauchy(0, 10), L ∼ LKJ(2)

S3 : βk ∼ N (0, 10000), φ ∼ Γ(2, 2),

2
2
ζ ∼ N (0, σζ
), σζ
∼ IG(0.1, 0.1), L ∼ LKJ(2)

S2 : βk ∼ N (0, 10000), φ ∼ Γ(3, 3),

2
2
ζ ∼ N (0, σζ
), σζ
∼ IG(0.1, 0.1), L ∼ LKJ(2)

S1 : βk ∼ N (0, 10000), φ ∼ Γ(2, 2),

O5 :Priors vary

Scenarios

0.01
(−0.23, 0.22)

−0.67
(−0.95, −0.38)

0.01
(−0.23, 0.24)

−0.67
(−0.97, −0.36)

0.01
(−0.22, 0.24)

−0.66
(−0.93, −0.36)

0.01
(−0.24, 0.24)

−0.65
(−0.94, −0.35)

0.01
(−0.22, 0.22)

−0.67
(−0.94, −0.39)

βˆ1
(95%HPD)

βˆ0
(95%HPD)

βˆ2

(−0.43, 0.08)

−0.17

(−0.42, 0.14)

−0.15

(−0.45, 0.09)

−0.17

(−0.43, 0.12)

−0.17

(−0.41, 0.09)

−0.17

(95%HPD)

(0.00,0.78)

0.31

(0.24, 1.07)

0.60

(0.00, 0.86)

0.32

(0.15, 0.95)

0.49

(0.02, 0.53)

0.22

(95%HPD)

σˆ0

Posterior means

(0.00, 0.92)

0.37

(0.23, 1.24)

0.69

(0.00, 1.06)

0.39

(0.15, 1.11)

0.56

(0.02, 0.64)

0.26

(95%HPD)

σˆ1

(−0.96, 0.64)

-0.23

(-0.99, 0.09)

−0.58

(−0.97, 0.63)

−0.24

(−0.99, 0.34)

−0.45

(−0.94, 0.66)

−0.13

(95%HPD)

ρ̂

φ̂

(0.16, 0.80)

0.48

(0.23, 0.87)

0.55

(0.23, 0.81)

0.51

(0.25, 0.84

0.55

(0.17, 0.74)

0.46

(95%HPD)

Table 2.5: Posterior summary for over-dispersed data with different choices of prior distributions

extreme number of seizures. Trends in seizure rates are not obvious from both the
graphs. In Figure 2.10, we present treatment arm-wise average weekly seizure rates,
and observe that at the end of eight weeks subjects in progabide group experience
lesser seizure rates.
Time is an indicator variable of a period after baseline (0 if baseline, 1 if after
baseline), trt is defined as 1 if a patient receives an anti-epileptic drug (progabide)
and 0 if placebo, Tij is the offset, length of time period in weeks (8 if baseline, 2 if
after baseline). By observing the profiles, it is reasonable to assume that there is a
natural heterogeneity among subjects both in their baseline level and in the changes
in expected counts over time, rationalizes the inclusion of subject-wise random effects
in the model.
We consider three models and mention them one by one:

M1 : A mixed effect model with subject-specific random intercept, and we
specify the model as

log(θij ) = xTij β + z Tij ζ i ,

(2.22)

where xTij = (1, trtij , timeij , trtij × timeij ), z Tij = 1, ζ i = (ζ0i ), β = (β0 , β1 , β2 , β3 )T .
More specifically,

log(θij ) = (β0 + ζ0i ) + β1 × trtij + β2 × timeij + β3 × trtij × timeij + log(Tij ) (2.23)

M2 : A mixed effect model with uncorrelated random intercept and slope.
With the general model noted in (2.22) the specifications are:
xTij = (1, trtij , timeij , trtij × timeij ), z Tij = (1, timeij ), ζ i = (ζ0i , ζ1i )T , β =
31

(β0 , β1 , β2 , β3 )T , and the variance-covariance matrix for random effects


2
σ0 0 
D=
.
0 σ12
In other words,

log(θij ) = (β0 +ζ0i )+β1 ×trtij +(β2 +ζ1i )×timeij +β3 ×trtij ×timeij +log(Tij ) (2.24)

M3 : A mixed effect model with correlated random intercept and slope. Following the similar notations in M1 and M2 the specifications are:
xTij = (1, trtij , timeij , trtij × timeij ), z Tij = (1, timeij ), ζ i = (ζ0i , ζ1i )T ,
β = (β0 , β1 , β2 , β3 )T , and the variance-covariance matrix for random effects




2
ρσ0 σ1 
 σ0
D=
.
2
ρσ0 σ1
σ1

In particular,

log(θij ) = (β0 +ζ0i )+β1 ×trtij +(β2 +ζ1i )×timeij +β3 ×trtij ×timeij +log(Tij ), (2.25)

In our analysis, we consider the following prior distributions:
φ ∼ LN (0, 15)
L ∼ LKJ(2)
ζq ∼ N (0, σζ2q ), σζ2q ∼ IG(0.1, 0.1) for q = 0, 1
βk ∼ N (0, 10000) for k = 0, 1, 2, 3
To fit the models M1 and M2 we do not require prior for L as the models do
not include correlation between random effects. We assume that βk can take any value
with normal mean 0 and standard deviation 10000. The dispersion parameter φ > 0
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and we assign a log normal prior with mean zero and moderate standard deviation for
φ. Choo-Wosoba et al. (2018) use log normal distribution as a prior for φ. Since σζ2i is
a scale parameter with a lower bound of zero, we assign a inverse-gamma prior for σζ2i ,
as suggested in Gelman et al. (2006). For the correlated random effects we assume
that the random effects are weakly correlated, the value η = 2, indicates that the
correlation ρ is close to zero. We perform Bayesian analysis by using Stan language
(named after Stanislaw Ulam, a mathematician) and rstan (R package) in four chains
with 5000 iterations having 2500 warm-up each. Since, from the simulation study we
obtain intuitive and consistent results across models for DIC, we report DIC for M1
and M2 . For M3 we report LPML, LOO, WAIC, and DIC for the model assessments
among the competing models CMP, NB and Poisson.
Table 2.6: Posterior summary under M1
Poisson

NB

CMP

Parameter
Mean

Std

95% HPD

Mean

Std

95% HPD

Mean

Std

95% HPD

R̂

β0

1.03

0.16

(0.71,1.34)

1.09

0.18

(0.74,1.45)

−1.19

0.13

(−1.44,−0.93)

1

β1

0.12

0.05

(0.02,0.21)

0.02

0.10

(−0.18,0.22)

−0.01

0.08

(−0.17,0.14)

1

β2

−0.03

0.22

(−0.47,0.42)

0.08

0.25

(−0.41,0.58)

0.98

0.05

(0.87,1.0)

1

β3

−0.10

0.06

(−0.23,0.02)

−0.32

0.14

(−0.60,−0.04)

−0.04

0.04

(−0.11,0.03)

1

σ

0.81

0.08

(0.66,0.98)

0.85

0.09

(0.68,1.02)

0.27

0.04

(0.20,0.36)

1

φ

-

-

-

0.15

0.03

(0.11,0.21)

0.30

0.04

(0.23,0.37)

1

DIC

6591.67

3291.92

2604.62

∆(Θ)

6439.85

3179.1

2561.15

152

113

44

pD (approx.)

The output of the models M1 , M2 , and M3 are reported in Tables 2.6, 2.7,
and 2.8 respectively. Table 2.6 presents posterior mean of the parameters obtained
from M1 for Poisson, NB , and CMP model, where σ indicates the standard deviation
of subject specific random intercept. The results show that σ = 0.27 is the least for
CMP model. Posterior mean for dispersion parameter φ both in NB (φ = 0.15)
and in CMP (φ = 0.30) postulate that the study data are over-dispersed. Although
not significant, the value β1 =−0.01, 95% HPD: (−0.17,0.14) in CMP model shows
that progabide has positive impact on number of seizures. The negative sign for the
interaction co-efficients in all three models reveal the beneficial effect of study drug in
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reducing number of seizures for epilepsy patients. The values R̂ = 1 for all parameters
in CMP model express that the posterior is close to the target distribution. The least
value of DIC (2604.62) for CMP illustrates the best fit in comparison to NB and
Poisson models.
Table 2.7: Posterior summary under M2
Poisson

NB

CMP

Parameter
Mean

Std

95% HPD

Mean

Std

95% HPD

Mean

Std

95% HPD

R̂

β0

1.05

0.15

(0.77,1.35)

1.09

0.16

(0.77,1.41)

-0.70

0.19

(−1.07,−0.31)

1

β1

0.02

0.12

(−0.21,24)

0.00

0.12

(−0.24,0.25)

0.02

0.10

(−0.17,0.21)

1

β2

0.06

0.20

(−0.34,0.47)

0.06

0.23

(−0.37,0.50)

0.73

0.09

(0.54,0.91)

1

β3

−0.31

0.16

(−0.62,0.00)

−0.32

0.17

(−0.66, 0.02)

−0.14

0.09

(−0.32,0.03)

1

σ0

0.75

0.08

(0.61,0.91)

0.75

0.09

(0.58,0.93)

0.34

0.06

(0.24,0.46)

1

σ1

0.52

0.07

(0.39,0.65)

0.42

0.11

(0.22,0.62)

0.24

0.05

(0.16,0.34)

1

φ

-

-

-

0.11

0.03

(0.07,0.17)

0.44

0.06

(0.34,0.56)

1

DIC

7612.10

3767.87

2899.88

∆(Θ)

7312.48

3617.93

2861.42

240

150
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pD (approx.)

We report posterior summary of the parameters for M2 from Poisson, NB ,
and CMP models in Table 2.7. Here we consider intercept and slope are independent.
We observe that σ0 = 0.34 and σ1 = 0.24 are the least(s) for CMP model. The values
φ = 0.11 for NB and φ = 0.44 for CMP evidence the existence of over-dispersion
in the data. The negative sign for the interaction between progabide and time coefficients in all three models reveal the beneficial effect of study drug in reducing
number of seizures for epilepsy patients, although not significant in case of CMP. The
values R̂ = 1 for all parameters in CMP model express good performance of MCMC
samples. Likewise M1 , the least value of DIC (2899.88) for CMP illustrates the best
fit of the model.
Posterior summary of the parameters for M3 from Poisson, NB, and CMP
models is presented in Table 2.8. The model considers correlated random intercept
and slope. We observe that σ0 = 0.30 and σ1 = 0.22 are the least(s) for CMP model.
The standard deviation of posterior means for all parameters in CMP model are the
least. The CMP model shows a significant correlation between random intercept and
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Table 2.8: Posterior summary under M3
Poisson

NB

CMP

Parameter
Mean

Std

95% HPD

Mean

Std

95% HPD

Mean

Std

95% HPD

R̂

β0

1.07

0.15

(0.78,1.34)

1.12

0.15

(0.83,1.1.42)

−0.79

0.19

(−1.14,−0.42)

1

β1

0.05

0.20

(−0.33,−0.45)

0.05

0.21

(−0.36,0.46)

0.01

0.09

(−0.16,0.19)

1

β2

0.00

0.12

(−0.23,0.23)

−0.03

0.12

(−0.26,0.20)

0.74

0.09

(0.56,0.91)

1

β3

−0.31

0.16

(−0.63,0.02)

−0.32

0.17

(−0.64,0.01)

−0.13

0.08

(−0.29,0.03)

1

σ0

0.75

0.08

(0.60,0.90)

0.68

0.09

(0.51,0.86)

0.30

0.05

(0.20,0.41)

1

σ1

0.52

0.07

(0.39,0.65)

0.37

0.09

(0.19,0.54)

0.22

0.04

(0.14,0.31)

1

ρ

0.14

0.16

(−0.17,0.43)

0.54

0.22

(0.06,0.91)

0.45

0.18

(0.08,0.78)

1

φ

-

-

-

0.12

0.03

(0.08,0.17)

0.41

0.06

(0.30,0.52)

1

LPML
LOO

−77.29

−63.29

−25.90

912.100

746.84

305.60

13,694.43

15,802.57

5,315.11

DIC

6,861.52

3,581.57

2,900.48

∆(Θ)

6727.94

3463.82

2878.90

134

118

22

WAIC

pD

slope resulting by ρ = 0.45 with a 95% HPD:(0.08, 0.78). The values R̂ = 1 for all
parameters in CMP model indicate good mixing of the MCMC samples. The highest
value of LPML (−25.90) and the least values of LOO (305.59), WAIC (5315.11), and
DIC (2900.46) for CMP model illustrate the best fit of the model among others.
The values φ = 0.12 for NB and φ = 0.41 for CMP illustrate that data are overdispersed. Although not significant, the negative sign for the regression coefficients of
the interaction between progabide and time in three models illustrate that progabide
has a positive impact in reducing number of seizures for epilepsy patients over time.
The regression parameter estimates in three models are not directly comparable since
θi does not represent mean of CMP as it does for NB and Poisson distributions. A
transformation, βk /φ provides a crude comparison with βk s from Poisson and NB
model (K. F. Sellers & Shmueli, 2010), which is almost accurate for larger counts
having mean greater than 10. Therefore, the converted coefficients for CMP are
β0 /0.41=−1.93, β1 /0.41=0.02, β2 /0.41=1.80, and β3 /0.41=−0.317. The coefficients
across models are quite different except for the interaction term. The interaction
coefficients in Poisson, NB, and CMP reveal 26.65%, 27.38% , and 27.17% reduction
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respectively in the seizure counts in progabide group from baseline to post baseline
in comparison to placebo group.
Although we produce trace plots, pair plots, and ACF plots for all parameters
form the three models M1 to M3 in CMP, NB, and Poisson model setting, we report
here only for CMP model under M3 . The trace plots in Figure 2.8 illustrates the
good mixing and convergence of MCMC samples for all parameters. The pair plots in
Figure 2.9 reveals density of the posterior means, and evidences no issues in MCMC
samples. The exponential shapes of ACF plots in Figure 2.10 for the regression
coefficients divulge a sign of non-auto correlated samples generation in MCMC.

2.6.2

Analysis of Multivitamin Supplementation in HIV Infected Adults Data

We illustrate another application of the proposed model to the data from a longitudinal randomized double-blinded placebo controlled clinical trial. The trial explores
the beneficial effect of multivitamin among HIV-infected adults receiving highly active antiretroviral therapy (HAART) in Uganda reported in Guwatudde et al. (2012).
The adults received either a multivitamin (MV) supplement (including vitamin Bcomplex, C, and E) or placebo. We consider 354 subjects each of having measurements
at visits 3, 6, 12, and 18 months for the analysis data set. The number of missing pills
(mean =14.03, variance=43.55) during last month of each visit as an indirect measure
of non-adherence to the study medication is considered as a response variable, and
trt (MV or Placebo) and weight measures of the subject at each visit are taken as the
covariates. We run the CMP model with uncorrelated random intercept and slope
with the similar notation mentioned in Section 2.6.1.
The form of the subject specific random effects models is

log(θij ) = (β0 +ζ0i )+β1 ×trtij +(β2 +ζ1i )×timeij +β3 ×log(weightij )+log(Tij ), (2.26)
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where Tij is the offset term. As an offset, we consider log 3 for the visits at 3, and 6
months, and log 6 for the remaining two visits.

We conduct the Bayesian analysis with the following prior specifications
φ ∼ LN (0, 15)
ζq ∼ N (0, σζ2q ), σζ2q ∼ IG(0.1, 0.1) for q = 0, 1
βk ∼ N (0, 10000) for k = 0, 1, 2, 3
Table 2.9: Posterior summary under the mixed effect model on Multivitamin supplementation in HIV infected adults data
CMP
Parameter
Mean

Std

95% HPD

R̂

β0

0.46

0.17

(0.14, 0.80)

1

β1

−0.02

0.02

(−0.05, 0.01)

1

β2

−0.33

0.01

(−0.34, −0.31)

1

β3

−0.01

0.04

(−0.09, 0.07)

1

σ0

0.07

0.01

(0.04, 0.09)

1

σ1

0.06

0.01

(0.05, 0.08)

1

φ

0.54

0.02

(0.50, 0.57)

1

From Table 2.9 we see, although not statistically significant, those who are
receiving multivitamin (β1 =−0.02, 95% HPD: (−0.05, 0.01)), and gaining weight
(β3 =−0.01, 95% HPD: (−0.09, 0.07)) are less likely to miss the intervention medication, indicating better adherence to the study medication. As the time of intervention
goes up adherence to the study medication (β2 =−0.33, 95% HPD: (−0.34, −0.31))
significantly increases. The values of R̂s = 1 for all parameters reveal good mixing of
the MCMC samples, and convergence of the model.
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2.7

Discussion

K. F. Sellers & Shmueli (2010) mentions, in terms of model fit and predictive power,
CMP model outperforms NB and Poisson by having its ability to account for a wide
variety of dispersion conditions in a parsimonious way. Due to the longer tail, CMP
model can capture extreme observations. As special cases, a number of data distributions such as Poisson, geometric, Bernoulli distributions can be generated from
CMP distribution. Instead of fitting separate models, the CMP model enables us
to fit a single model for various dispersion conditions. This distinctive feature introduces CMP model as a flexible regression model for count data. In this study we
propose a novel Bayesian approach to fit a CMP generalized mixed effect model by
using No-U-Turn Sampling (NUTS), a variant of Hamiltonian MCMC. In particular,
we incorporate random intercept and slope in CMP mixed effect model to capture
subject specific heterogeneity and inherent dispersion prevailing in the longitudinal
count data. We examine the model performance based on both simulated and real
data by using four Bayesian model assessment criteria namely, LPML, LOO, WAIC,
and DIC. Especially, we simulate data in under-, over-, and equi- dispersed conditions and apply Poisson, negative binomial, and CMP model in each of the dispersion
conditions.
We experience from both simulated and real data analysis that each of the
model assessment criteria does not equally perform in all situations, similar evidence
mentioned in Vehtari et al. (2017). From the simulated data we see that WAIC
and DIC perform consistently in all situations. On the contrary, both LOO and
LPML performances are conflicting in case of under-and equi-dispersed data with
subtle deviations. We experience, in case of epilepsy data all four measurements are
giving similar conclusion. A close look to CPO calculation for epilepsy data reveals
that for some data points it provides unusual value for CPO which impacts LPML.
Calculation of Monte-Carlo version of LOO is also similar to CPO calculation, and
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probably that is why they behave similarly. In addition, WAIC involves calculation of
variance of log posterior likelihood across simulations is not reliable when it exceeds
0.04 (Vehtari et al., 2017). Therefore, it is reasonable to rely on DIC, at least for
this case as it is widely used method although retains some limitations (Vehtari et
al., 2017; Plummer, 2008; Van Der Linde, 2005).
In Our study, based on DIC, both the simulation and real data analysis reveal
that CMP model fits better than NB and Poisson for over- or under-dispersed data.
In case of under-dispersed simulated data, surprisingly, we observe that parameter
estimates in Poisson and NB model almost equivalent, while a bit different than that
of CMP model. K. F. Sellers & Shmueli (2010) found similar results in their analysis.
Therefore, it is reasonable to say that in case of under-dispersed data both Poisson and
NB produce similar results. The CMP model retains the lowest WAIC and DIC but
MSEs for the parameters are higher or equal except for the intercept in comparison
to other models. Poisson and NB are not optimal model for under-dispersed data.
Although predictive performance is not satisfactory, based on DIC and WAIC, the
CMP model may be viewed as the best model followed by Poisson. However, an
extensive simulation study by considering a wide range of under-dispersion levels and
true effect size may result different conclusion. In case of over-dispersed simulated
data we experience that CMP is the best model followed by NB. Poisson seems to be
the best model for equi-dispersed data while CMP is the second alternative.
The regression parameter estimates in three models are not directly comparable since θi does not represent mean of CMP distribution like of NB and Poisson
distributions. A conversion, βk /φ provides an approximate comparison with βk s from
Poisson and NB model (K. F. Sellers & Shmueli, 2010) for high counts. After transformation, head to head comparisons reveal that parameter estimates are different at
least for some cases. By choosing an incorrect model there remains potential chance
of loosing information on the effect sizes of the covariates of interest.
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The sensitivity analysis with over-dispersed data illustrates that when LKJ
density approaches to uniform type of shape the posterior means of standard deviations and correlation become more sensitive while a little sensitivity is noticed in case
of regression coefficients.
Epilepsy data are well studied in literature, and results are known regarding
dispersion and efficacy of progabide, a study drug. We examine whether our proposed
model could produce the similar results. The data are over-dispersed, and most of
the studies resulted non-efficacy of the progabide (Leppik et al., 1987). Our model
sufficiently produced the similar results to the previous studies. The model fitting on
multivitamin data to assess the adherence to medication in terms of missing pills also
depicts good convergence.
In epilepsy data analysis we encounter some unusual CPO values, and high
values of variance of log posterior likelihood across simulations that makes the reliability of LPML and WAIC questionable, need further exploration. In this study we
did not deal with zero inflated longitudinal counts, missing mechanism of longitudinal data, and modeling duel links (modeling log link of dispersion parameter) in the
context of CMP distribution which remains for further extension. In all cases the
model checking by Rhat, trace plots, pair plots,ACF plots were quite satisfactory.
With the advent of computation performed in this study, dealing with count
response, the proposed model is easily extendable to study subject and cluster specific
variability in multi-site clinical trials by adding cluster or site specific random effects in
the model. The model would be potentially useful and superior in biomedical, public
health, and business research while dealing with dispersed periodic count responses.
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Figure 2.1: LKJ density plot for 2 × 2 Correlation Matrix Ω

Figure 2.2: Boxplot for subject-wise CPO for CMP model with φ = 2.50
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Figure 2.3: Comparison of posterior means of regression parameters with changing β
prior parameters

Figure 2.4: Comparison of posterior means of regression parameters with changing φ
prior parameters
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Figure 2.5: Comparison of posterior means of regression parameters with changing
σζ2 prior parameters

Figure 2.6: Comparison of posterior means of regression parameters with changing L
prior parameters
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Figure 2.7: Comparison of posterior means of regression parameters with changing
prior distributions

Figure 2.8: Profiles of seizure rates for selected subjects
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Figure 2.9: Treatment arm-wise profile of seizure rates

Figure 2.10: Weekly average seizure rates
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Figure 2.11: Trace plots for M3 (CMP model)

Figure 2.12: Pair plots for M3 (CMP model)

Figure 2.13: ACF plots forM3 (CMP model)
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Chapter 3
Bayesian Generalized Additive
Model for Longitudinal Count
Data Distributed as
Conway-Maxwell Poisson
3.1

Introduction

The parametric model, such as linear mixed effect model assumes that the shape
of the functional relationship between mean of the longitudinal response and covariates is known and linear. The parametric model explains the relationship with a
relatively smaller number of regression coefficients, maintains model parsimony, and
keeps parameter interpretation simple. However, in clinical trials and observational
studies, there are situations where a non-linear relationship exists between response
and prognostic factors (T. J. Hastie & Tibshirani, 1990). In such a situation, using fewer parameters may be too restrictive in capturing the non-linear functional
relationship. Longitudinal model has to allow grater flexibility to account for the
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relationship via non/semi-parametric modeling approach. In non-parametric regression model, the shape of the functional relationship is not settled down in advance,
instead, it is largely determined by the data itself (G. M. Fitzmaurice et al., 2012).
In practice, we encounter count data analysis arising from a variety of studies
(e.g, cross-sectional, longitudinal or clustered). Likewise, linear mixed effect model,
the generalized linear parametric model may not be flexible to capture non-linearity
between the link function and covariates while modeling count data. To address the
situation, we can add more flexibility in the model by replacing the linear predictor
with splines. The resulting model is termed as generalized additive model (GAM).
According to T. J. Hastie & Tibshirani (1990), the GAM prevents model misspecification, hence provides reasonable inference for the parameters of interest. The GAM
was studied in the literature by using count data with Poisson and Negative Binomial distributional assumptions including their zero-inflated variants in Harezlak
et al. (2018). The available packages dealing with GAM do not support ConwayMaxwell Poisson (CMP) distributional assumption of the count data. To the best
of our knowledge, no literature is available regarding GAM with longitudinal data
distributed as CMP both in frequentist and Bayesian settings. In order to capture
non-linearity between link function and covariates, to account for subject-specific heterogeneity, and to avoid integrational complexity (discussed in Chapter 2) we propose
a Bayesian generalized additive mixed model (BGAMM) for longitudinal count data
distributed as CMP.
This chapter is organized as follows. Section 2 includes the proposed statistical
model following Bayesian inference in Section 3. An illustration of the proposed
model with an application to a hypothetical data is presented in Section 4, and a
short discussion is noted in Section 5, and full conditionals in Appendix B.
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3.2
3.2.1

The Proposed Model
General form of B-Spline model

A spline of degree F is a function constructed by connecting polynomial segments
of degree F so that the function is continuous, has (F − 1) continuous derivatives,
and F th derivative between knots is constant. The linear mixed effect model of
penalized splines for longitudinal response demonstrates that the mean response is
a function of fixed effects, and two sets of random effects. The first set of random
effects ζi allows each individual to have her/his own piece-wise linear curve that is
offset from the smooth population averaged curve by ζi for i = 1, . . . , I, and the
additional random effects, γc for c = 1, . . . , C, are the coefficients for the truncated
line functions, (tij −Sc )+ for j = 1, . . . , ni , that produce a smooth regression function,
Ψ(tij ). The amount of smoothing depends on the relative value of variance of γ (σγ2 ).
The γc takes care of the non-linear trend in the mean response, and ζi , varying across
subjects, accounts for correlation among the repeated measures. To fix this idea, we
consider the following expression

E(yij |X) = X i β + Ψ(tij ) + ζi ,

(3.1)

where, X i β is the parametric part, a linear function of covariate X, and Ψ(tij ) =
PC
c=1 γc (tij − Sc )+ is the nonparametric part, (tij − Sc )+ = (tij − Sc ) if (tij − Sc ) > 0,
and equal to zero otherwise. The Sc are the knot locations in the piece-wise linear
function of time tij , yij denotes the jth response on the ith individual at time tij ,
ζi ∼ N (0, σζ2 ), and γc ∼ N (0, σγ2 ).
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3.2.2

Statistical Model

Let y i = (yi1 , . . . , yini )T be the independent count response vector of subject i for
i = 1, . . . , I and j = 1, . . . , ni , X i = (xi1 , . . . , xini )T be a (ni ×(p+1)) design matrix of
fixed effect covariates, where xTij = (1, xij1 , . . . , xijp ) is a (p + 1) dimensional covariate
vector, Z i = (z i1 , . . . , z ini )T be a (ni × C), (C ≤ (p + 1)) known design matrix, where


T
z ij = (xij1 −S1 )+ , . . . , (xij1 −Sc )+ , . . . , (xij1 −SC )+ is a C-dimensional basis vector,
ζ = (ζ1 , . . . , ζI )T is the subject specific random intercept vector, ζ̃ i = (ζi , . . . , ζi )T , a
ni dimensional vector, and β = (β0 , β1 , . . . , βp)T is a (p + 1) dimensional fixed effect
co-efficient vector, γ = (γ1 , γ2 , . . . , γC )T is a C dimensional spline coefficient vector.
Then, a generalized additive mixed effect model (GAMM) is given by



E(y i |β, γ, ζ̃ i ) = g −1 X i β + Z i γ + ζ̃ i ,

(3.2)

where g −1 (·) is link function.
Further, let θij be the shape parameter of CMP distribution associated with
jth component of y i . Then, the GAMM for longitudinal count response (distributed
as CMP) is given by

log(θij ) = xTij β + z Tij γ + ζi ,
where ζ ∼ N (0, σζ2 ), and γc ∼ N (0, σγ2 ).
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(3.3)

3.2.3

The Likelihood Function

By considering the random effects as latent variables, the complete data likelihood
can be written in the following form

L(β, γ, φ, ζi ) =

"n
I
i
Y
Y
i=1

#
f (yij |β, γ, φ, ζi )f (ζi | σζ2 ) .

(3.4)

j=1

When response yij distributed as CMP we can write equation (3.4) as

L(β, γ, φ, σζ2 )

3.3

φ
ni 
I Y
Y
yij
1
=
× exp xTij β + z Tij γ + ζi
yij !
i=1 j=1
k !−1
P∞
T
T
exp
x
β
+
z
γ
+
ζ
i
ij
ij
k=0
×
φ
(k!)
I

Y
ζ2 
× (2πσζ2 )−(1/2) exp − i 2 .
2σζ
i=1

(3.5)

Bayesian Inference

The Bayesian modeling needs specification of prior distributions for the parameters under consideration, and generation of the corresponding posterior distribution.
Then, obtaining MCMC samples from the posterior distribution by using suitable
samplers, and generating posterior summary (means) to avoid complex or intractable
integration. Bayesian analysis enables us to explore different characteristics of the
parameters. Inclusion of zeros in the 95% HPD intervals of the regression parameters
reveal the non-significance of the respective traits associated with the parameter.

3.3.1

Priors and Posteriors

In order to fit a BGAMM, we assume that β, γ, σζ2 , and φ are independent apriori.
Then
π(β, γ, φ, σζ2 ) = π(β) × π(γ) × π(φ) × π(σζ2 ).
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(3.6)

We further assume that, β∼ Np (β 0 , Σ0 ), γ ∼ Nq (γ 0 , Σγ ), φ ∼ LN (µφ , ψ),and σζ2 ∼
IG(α, δ). Then the posterior distribution under the proposed model is given by

"
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I Y
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1=1

i=1 j=1

∝

#

1
2



(γ − γ 0 )

T

Σ−1
γ (γ

− γ 0)

yij
i
 h
(β
−
β
)
exp − 12 (β − β0 )T Σ−1
0
0
1

|Σ0 | 2



I

Y
ζi2 
2 −(1/2)
×
× (σζ )
exp − 2
1
2σζ
|Σγ | 2
i=1
 
2 
φ
 δ  exp − 12 logφ−µ
ψ
δ α −2(α+1)
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exp −
×
.
×
Γ(α) ζ
α
ψφ
(3.7)

3.4

Illustration of GAM

We illustrate the proposed model with a hypothetical data example. Data consist
of count measurements from 50 subjects in five occasions (at different ages of the
subjects). The continuous age variable is generated from normal distribution with a
standards deviation 2 and a randomly selected mean from uniform distribution having a support (15, 50). The age variable is considered as varying time in the mixed
effect GAM (no fixed time points of measurements). The range of age in analysis
data is (51.10 − 13.12) years. Treatment variable is generated from Bernoulli distribution with probability, pr = 0.55. We generate under-dispersed count data as
yij ∼ CM P (50 × 5, θij , 1.8), where the positive shape parameter θij is generated by
taking an absolute value of a term simulated from normal distribution with standard
deviation 1 and a randomly selected mean from uniform distribution with a support
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(1, 2). The mean and variance of the count response are 0.812 and 0.578 respectively.
The Figure 3.1 illustrates the shape of count response distribution. The relationship
between age vs count response, and age vs log(count response) along with their respective trends and 95% confidence intervals are presented in Figures 3.2, and 3.3 (a)
and (b) respectively. In both cases we notice that the relationships are non-linear
even after taking logarithmic transformation of the counts. This situation leads us to
the use of generalized additive model.

3.4.1

Specific model

In a two group setting (study drug vs control, exposed vs non-exposed) the time
trend can be incorporated in semi-parametric fashion by allowing the mean response
change in a highly non-linear and non-predetermined way. This set up could be very
inviting in clinical trials where a pre-determined analysis plan is required but the
actual form of mean time trend is not known in advance. The group effect is added
in a parametric way that allows a relatively simple and powerful test of it on the
mean change over time. Therefore, we include treatment (trt) as a covariate in the
model to examine the treatment effect on the function of mean count change. We fit
Poisson, Negative binomial (NB), and CMP model with B-spline and perform model
assessments by using DIC, LPML, LOO, and WAIC.

We specify a mixed effect GAM with subject-specific random intercept as

log(θij ) = xTij β + z Tij γ i + ζi ,

(3.8)

where xTij = (1, trtij , ageij , trtij × ageij ), ζqi = (ζ0i ), β = (β0 , β1 , β2 , β3 )T , and
γ = (γ1 , . . . , γC )T , and the basis vector for B-spline is z Tij = [(ageij −S1 )+ , . . . , (ageij −
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SC )+ ].

More specifically,
log(θij ) =β0 + β1 × trtij + β2 × ageij + β3 × trtij × ageij
(3.9)
+ γ1 × (ageij − S1 )+ +, . . . , +γC × (ageij − SC )+ + ζi ,
In fitting a spline regression, knots are usually specified in advance. The exact
locations and number of knots (C) usually not too sensitive to the predictive value of
the regression (Harrell Jr, 2013). A good number of approaches have been discussed
in the literature to select the number of knots, and places in the generalized additive
model (GAM) setting. Some of them are heuristic (Harrell Jr, 2013), and some of
them are statistical method based (Wood & Wood, 2015). Harrell Jr (2013) suggests
if the sample size, n ≥ 100 then C = 5, and if n ≤ 30 then C = 3. The function gam()
in R package mgcv (Wood & Wood, 2015) uses generalized cross-validation (GCV)
approach that automatically chooses the number of knots for the model. However,
mgcv package does not support CMP distribution. Akaike information criterion (AIC)
can also be used to choose the number of knots in a GAM fitting (Van Houwelingen
& Le Cessie, 1990). This approach chooses C to maximize model likelihood ratio
χ2 − 2C (Harrell Jr, 2013).
Once, the number of knots is chosen we can use them in equally spaced locations. However, other options can also be applied. Some of the alternative approaches
can be mentioned here. In most cases, researchers use 3 to 5 of knots and they are
placed at fixed percentiles of the data.

Harrell Jr (2015) suggested heuristic per-

centiles which is popular to the biostatisticians. If the sample size is less than 100,
Stone & Koo (1985) suggested replacing outer quantiles with 5th smallest and 5th
largest and the inner three quantiles at equally spaced positions of the variable. How-
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ever, in our analysis we use C = 30 arbitrarily to increase the model complexity, and
to observe the model implementation time via our code.
The model assumes a single realization of (γ1 , . . . , γC ), and these C random
coefficients are shared by all individuals. These random coefficients must be constrained to have the same variance σγ2 to avoid non-convergence in model fitting
(G. M. Fitzmaurice et al., 2012). Bayesian analysis takes care the uncertainty in
smoothing parameters. Therefore, the assumption γc ∼ N (0, σγ2 ) is appropriate if we
use O’Sullivan Spline (Harezlak et al., 2018). O’Sullivan penalized splines imitates the
natural boundary behavior of smoothing splines (https://arxiv.org/abs/0707.0143).
We are using such splines in our analysis. Harezlak et al. (2018) implemented a GAM
with normally distributed response in rstan in Bayesian setting. We implement here
a similar setting with different distributional assumption of count data.
In our analysis, we consider the following prior distributions
φ ∼ LN (0, 15)
ζ ∼ N (0, σζ2 ), σζ2 ∼ IG(0.2, 0.2)
βk ∼ N (0, 10000) for k = 0, 1, 2, 3
γc ∼ N (0, σγ2 ) for c = 1, . . . , 30, and
σγ2 ∼ IG(0.2, 0.2)
We assume that βk can take any value with normal mean 0 and standard
deviation 10000. The dispersion parameter φ is positive, 0 < φ < 1 indicates overdispersion, and φ > 1 indicates under-dispersion. We assign a log normal prior with
mean zero and moderate standard deviation for φ. Wosoba et al. (2018) use log
normal distribution as a prior for φ. Since σζ2 is a scale parameter with a lower bound
of zero, we assign a inverse-gamma prior for σζ2 , as suggests in Gelman et al. (2006).
We perform Bayesian analysis by using Stan language and rstan R package in four
chains with 10000 iterations having 2500 warm-up each. We report LPML, LOO,
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WAIC, and DIC for the model assessments among the competing models such as
CMP, NB and Poisson. The results are presented in Table 4.1.
Table 3.1: Posterior summary under Poisson, NB, and CMP model
Poisson

NB

CMP

Parameter

Mean

Std

95% HPD

R̂

Mean

Std

95% HPD

R̂

Mean

Std

95% HPD

R̂

β0

−1.11

0.44

(−1.98,−0.24)

1

−1.12

0.46

(−2.01,−0.22)

1

−1.07

0.57

(−2.17,0.05)

1

β1

0.66

0.56

(−39,1.78)

1

0.65

0.58

(−0.46,1.82)

1

1.00

0.72

(−0.42,2.40)

1

β2

0.03

0.01

(0.00,0.05)

1

0.02

0.01

(0.00,0.05)

1

0.04

0.02

(0.01,0.07)

1

β3

−0.02

0.02

(−0.05,0.01)

1

−0.03

0.02

(−0.06,0.01)

1

−0.03

0.02

(−0.08,0.01)

1

σζ

0.15

0.07

(0.04,0.28)

1

0.15

0.07

(0.04,0.28)

1

0.25

0.13

(0.05,0.49)

1

σγ

0.16

0.08

(0.04,0.33)

1

0.17

0.08

(0.04,0.33)

1

0.21

0.12

(0.04,0.43)

1

φ

-

-

-

-

0.03

0.02

(0.01,0.07)

1

2.16

0.30

(1.57,2.73)

1

DIC

1011.44

977.62

721.34

768.47

571.77

632.44

226

209.15

89

−27.15

−13.92

0.37

LOO

2715.09

1392.65

−36.43

WAIC

2034.88

1493.28

719.64

∆(Θ)
pD (approx.)
LPML

Posterior summary of the parameter φ = 2.16 from CMP model reveals that
data are under-dispersed as we assumed while simulation. The values for R̂ for all
parameters in all models illustrate good performances of the model. The DIC values
for Poisson, NB, and CMP models are 1011.44, 977.62, and 721.34 respectively. The
smallest values of DIC (721.34), LOO (−36.43), WAIC (719.64), and highest value of
LPML (0.37) for CMP model, illustrate the best fit of the CMP model in comparison
to Poisson and NB model. Likewise in chapter 2, we notice that both Poisson and
NB model produce similar parameter estimates as the data are under-dispersed, but
different from CMP model outputs. The converted regression coefficients for CMP
model are β0 /2.16 =−0.50, β1 /2.16 =0.46, β2 /2.16 =0.02, β3 /2.16 =− 0.01 are also
a bit different from other models.
We produce trace-plots, density plots, plot for Metropolis acceptance rate, histogram for R̂ and ACF plots for all parameters from CMP, and reported them in
Figures 3.2 to 3.6 respectively. The caterpillar like shape of the trace plots depict
the good mixing of the posterior samples across chains. The bell shapes of density
plots for posterior means for all parameters depict non-disruption in MCMC sam56

pling process. In Figure 3.4 we observe that log posterior is bell shaped which is an
indication of better convergence of the model. The mean metropolis acceptance rate
also high. The average R̂ is closer to 1 reveals that posterior distribution is close
to the target distribution. Exponential shape of ACF plots in Figure 3.6 stipulates
relatively lesser auto-correlated samples generation which is an advantage of using
Hamiltonian samplers (No-U-Turn samplers) over other MCMC sampling techniques.

3.5

Discussion

Dealing with generalized linear model (GLM), K. F. Sellers & Shmueli (2010) opines
that CMP model is a better alternative to NB and Poisson while count data exhibit dispersion. However, the application of CMP generalized additive mixed model
dealing with longitudinal count data was unexplored in literature. In this study we
attempt to examine alternatives of GAM by considering usual count data distributions such as CMP, NB, and Poisson by using a hypothetical dataset. The response
data here is under-dispersed. From the analysis dataset we notice that CMP model
with B-spline fits better than NB and Poisson model on the basis of all Bayesian
model assessment criteria we did consider. A crude comparison of model regression
parameters across models is possible with a suitable conversion (βk /φ) of CMP model
coefficients, we perform this point-wise comparison across models. We experience that
both Poisson and NB model result almost same values for respective parameters that
conforms similar findings by Sellers et al.(2010) for under-dispersed data. However,
the values are different in case of CMP model.
We do not accommodate automated knot selection in GAM in CMP distributional setting. In fact, no package is available for selecting number of knots and
implementing GAM when count data distribution is assumed as CMP. The heuristic
percentiles for knot location suggestion by Harrell Jr (2015) may be followed. The
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other alternatives might be followed by fitting GAM using mgcv R package with the
logarithmic link by considering either Poisson or Negative Binomial or both to determine C first and then use that C in CMP setting. We can also check model fitting
by calculating DIC for different choices of C and determine the value of C based on
the lowest DIC value. However, use of excessive number of knots might minimize the
roughness of the non-linear curve with a high chance of producing over-fitting model
(G. M. Fitzmaurice et al., 2012). The GAM is extremely useful to study the efficacy
of the intervention drug or devices in clinical trials where functional relationship between mean count response and time is found to be non-linear. We were limited due
do unavailability of a good real data set to explore a scientific research question of
interest in CMP GAM setting which remains for further exploration. In addition, we
do not consider zero inflated longitudinal counts, missing data issues, and duel links
(modeling log link of dispersion parameter) in CMP GAM fitting which also remain
for further extension.
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Figure 3.1: Distribution of the data

Figure 3.2: Relationship between counts and age
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Figure 3.3: Relationship between log(counts) and age

Figure 3.4: Trace plots for CMP model with B-spline
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Figure 3.5: Density plots for CMP model with B-spline

Figure 3.6: Metropolis acceptance rate for CMP model with B-spline
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Figure 3.7: Histogram for Rhats for CMP model with B-spline

Figure 3.8: ACF plots for CMP model with B-spline
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Chapter 4
Association Between Multivitamin
Supplementation and Overall
well-being in HIV
Patients:Application of the
Bayesian Generalized Mixed Effect
Model
4.1

Introduction

There has been a substantial decrease in the number of new HIV infections during the
past decade. However, recent estimates from United States indicate that there were
36,400 new cases in 2018 and an estimated 1.2 million people had HIV (prevalence)
(for Disease Control et al., 2020). The advent of highly active combined antiretroviral therapy (cART) has tremendously altered the natural history of HIV infection
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transforming the disease from a fatal infectious one to a manageable chronic condition
(Deeks et al., 2013). With an enhanced life expectancy, the patterns of comorbidities
have changed among the HIV-infected population. Along with the continued management of the HIV infection, this population needs care of age-related comorbidities
which may be complicated by issues such as medication associated toxicities (Chu &
Selwyn, 2011). Given the situation, there is continued need to exploit all potential interventions to improve the health and health related quality of life of the HIV-infected
population, and nutritional interventions are one of them.
Chronic diseases in general, have certain underlying pathologic mechanisms
that may be modified by nutrients such as reduction of oxidative damage by antioxidants, DNA methylation regulated by folate and B vitamins, bone metabolism
regulated by vitamin D and calcium, and cell differentiation, proliferation, and growth
regulated by retinol, calcium, and vitamin D (H.-Y. Huang et al., 2006). Also, it is
well established that chronic diseases lead to micronutrient deficiencies that in turn
further increase the risk of disease progression and symptomatology (Erickson et al.,
2000). Thus, micronutrient supplementation may be beneficial in disease mitigation.
Regarding HIV-infected population, vitamin D supplementation has been studied
extensively. Recent studies have found that vitamin D supplementation attenuates
the effect of immune activation and decreases bone turnover markers in HIV-infected
population (Eckard et al., 2018; Nanayakkara et al., 2019; Sudjaritruk & Puthanakit,
2017).
The potential beneficial role of multi-micronutrient supplementation has been
evaluated to a relatively lesser extent in the HIV-infected population. Interventional
studies conducted on HIV-infected children have shown micronutrient supplementation beneficial in terms of improvement in CD4 counts, delay in the progression of
disease, improved appetite, reduced duration of pneumonia or diarrhea and improved
wasting (Gautam et al., 2014; Mda et al., 2010, 2013).
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However, the interventional studies conducted on adult HIV-infected population exhibit mixed result probably dependent on the characteristics of the study
population or statistical analysis used. Majority of the studies conducted on adult
participants, evaluated the micronutrient supplementation through improvement in
biomarkers and mortality as the outcomes, and not through the disease symptomatology. Where some studies found improved CD4 counts, reduced viral loads, decreased
mortality and reduced risk of AIDS defining condition with micronutrient supplementation (Baum et al., 2013; Hemsworth et al., 2012; Zhao et al., 2009; Kaiser et al.,
2006; Jiamton et al., 2003), others did not find any beneficial result (Makinde et al.,
2017; Motswagole et al., 2013; PrayGod et al., 2011; Semba et al., 2007).
Given the contradictory findings of the limited multi-micronutrient interventional research conducted in the adult HIV-infected population, the subject needs
further evaluation, specially in terms of an effect on the overall symptomatology of
the disease. To fill the research gap, our study is using data from a randomized
double-blind controlled trial to determine the effect of multivitamin supplementation
(containing 1.4 mg B1, 1.4 mg B2, 1.9 mg B6, 2.6 mcg B12, 18 mg niacin, 70 mg C,
10 mg E, and 0.4 mg folic acid) in adult HIV-infected participants on overall disease
symptomatology, where overall well-being of the patients accounts for the reduction
in counts of sign and symptoms due to study drug.
A variety of regression models based on the Poisson distribution namely standard Poisson, negative binomial, restricted generalized Poisson regression model have
been used to model such kind of count data (Winkelmann & Zimmermann, 1995).
However, these models are based on certain assumptions. For example, Poisson model
assumes equality of mean of variance. In practice this ideal situation happens rarely,
instead, variance could be higher (over-dispersion) or lower (under-dispersion) than
mean. Failure to address these properties may lead to the inefficient estimation of
the model parameters. The Conway-Maxwell Poisson (CMP) as a count data distri65

bution is able to accommodate a wide range of dispersion in the data and has been
proven superior to the alternative models (K. F. Sellers & Shmueli, 2010). To our
knowledge no previous interventional study has used the Bayesian generalized linear
mixed model (BGLMM) which enables us to deal with over/under dispersed longitudinal counts of sign and symptoms, especially when the count data follow CMP
distribution. The first objective is to demonstrate the applicability of this model
as an alternative to study disease symptomatology, and the second objective is to
find the association between multivitamin supplements and overall well-being of the
HIV patients. The second section of this study includes methods along with data
source, response variable, predictor variables, model and statistical analysis. The
results are included in Section 3 followed by discussion and conclusion in Section 4.
We demonstrate CMP model implementation coding in the final Section.

4.2
4.2.1

Methods
Data Description

The longitudinal data for this study are collected from a randomized double-blind
placebo controlled clinical trial conducted to examine the beneficial effect of multivitamin among HIV-infected adults receiving highly active antiretroviral therapy
(HAART) in Uganda reported by Guwatudde et al. (2012). In this trial 400 adults
are randomly assigned to either a multivitamin (MV) supplement (including vitamin
B-complex, C, and E) or placebo arm with equal proportion who were continuing to
receive standard medical care according to Uganda’s Ministry of Health guidelines.
The current study utilizes the data from 354 subjects for whom complete measurements at 3, 6, 12, and 18 months visits were available. In every visit, the subjects
were asked whether they experience any sign and symptoms during last three months
in forty five directions such as fatigue, general body weakness, fever, oral thrush etc.
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By combining individual answers we create a response variable, namely, the number
of symptoms and sign as an indication of overall well-being of the patients. Decrease
in the number of sign and symptoms may be viewed as improved health condition
of the subjects. The trial collected background and demographic information of the
subjects, among them baseline age and gender information were available. Whether
the subject receives multivitamin or placebo, baseline age , and gender of the subjects
are adjusted in the model as the the covariates.

4.2.2

Statistical Analysis

Let θij be the shape parameter of CMP distribution associated with jth component
of longitudinal count response vector y i for subject i. Then, under the notations
defined in Chapter 2, the specific model to study number of sign and symptoms is
given by

log(θij ) = (β0 + ζ0i ) + β1 T rtij + (β2 + ζ1i )T imeij + β3 Age + β4 Gender,

(4.1)

where ζ0i and ζ1i are the subject specific random intercept and slope respectively, and
we assume they are correlated. The βs are the regression coefficients.
We perform Bayesian analysis in Stan language and rstan in four chains with
5000 iterations having 2500 warm-up each. By default Stan uses No-U-Turn Sampling
(NUTS), an adaptive version Hamiltonian MCMC. In our analysis we consider the
following prior distributions: βk ∼ N (0, 10000) for k = 0, 1, 2, 3, 4, a diffuse normal
prior. The dispersion parameter φ ∼ LN (0, 15), providing positive support for φ.
We assign ζq ∼ N (0, σζ2q ), σζ2q ∼ IG(0.1, 0.1) for q = 0, 1, as suggested in Gelman
et al. (2006). For the correlated random effects we decompose correlation matrix
Ω with Choleskey decomposition Ω = LT L, where L is a lower triangular matrix,
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and its distribution is assumed as LKJ(η). We assume that the random effects are
weekly correlated, the value η = 2, indicates that the correlation is close to zero. We
fit Poisson, negative binomial (NB) and CMP model, and compared fitness of the
models by using DIC, WAIC, LOO, and LPML.
A subgroup analysis has been conducted by segregating the data by sex with
CMP model. In subgroup analysis intervention (MV or Placebo) and age are considered as the covariates. The regression parameter estimates from CMP model are
not directly comparable with Poisson and NB as CMP model does not model link
function of the mean directly. A transformation (βk /φ) is used to compare coefficients across three (Possion, NB, and CMP) models as suggested in K. F. Sellers &
Shmueli (2010). Inclusion of zeros in 95% HPD intervals for coefficients are considered as non-significance of the respective covariates. We report incidence rate ratio
(IRR) for each of the covariates. An IRR< 1 indicates positive impact of the trait on
reducing number of signs and symptoms.

4.3

Results

We analyzed data from 354 HIV infected subjects of ages 18-67 years with a median
age 36 years (IQR=11), among them 173 (48.87%) received multivitamin and the rest
received placebo. Male participants are 108(30.5%). The response variable ranges
from 0 to 31 with a median sign and symptom count 7 (IQR=6).
In Table 4.1, we report posterior means, standard deviation, and 95% credible intervals for the parameters obtained from Poisson, negative binomial, and CMP
model outputs. In Figure 4.1, we illustrate posterior means of the CMP model parameters along with their 95% HPD intervals. The value of dispersion parameter
(φ = 0.84) in CMP model indicates that data are over-dispersed. The CMP model
retains the lowest DIC (6918.71), LOO (693.48), WAIC (7048.49), and the highest
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Table 4.1: Posterior summary under Poisson, Negative binomial and CMP model
Poisson

NB

CMP

Parameter
Mean

Std.

95% HPD

Mean

Std.

95% HPD

Mean

Std.

95% HPD

R̂

β0

2.25

0.11

(2.02,2.46)

0.81

0.06

(0.71,0.92)

1.89

0.14

(1.61,2.16)

1

β1

−0.10

0.05

(−0.20,0.00)

−0.05

0.03

(−0.10,0.00)

−0.09

0.05

(−0.17,0.01)

1

β2

−0.03

0.00

(−0.03,−0.02)

−0.01

0.00

(−0.02,−0.01)

−0.02

0.00

(−0.03,−0.02)

1

β3

0.00

0.00

(−0.01,0.01)

0.00

0.00

(0.00,0.00)

0.00

0.00

(−0.01,0.00)

1

β4

−0.26

0.06

(−0.37,−0.14)

−0.13

0.03

(−0.19,−0.07)

−0.22

0.05

(−0.32,−0.12)

1

σ0

0.47

0.03

(0.41,0.53)

0.20

0.0.02

(0.17,0.24)

0.38

0.04

(0.31,0.46)

1

σ1

0.03

0.00

(0.02,0.03)

0.01

0.00

(0.01,0.02)

0.02

0.00

(0.01,0.02)

1

ρ

−0.32

0.10

(−0.50,−0.12)

0.03

0.16

(−0.27,0.36)

−0.24

0.13

(−0.49,0.02)

1

φ

-

-

-

0.03

0.01

(0.01,0.04)

0.84

0.05

(0.75,0.93)

1

DIC
pD (approx.)
LPML
LOO
WAIC

7149.73

18650.71

6918.71

416

52

305

−361.89

−1044.88

−346.74

723.79

2089.75

693.48

7211.97

19244.44

7048.49

Figure 4.1: Posterior summary of the parameters from CMP model with 95% Credible
Interval
(−346.74) among the three models which indicate that the CMP model fits better
than Poisson, and negative binomial models. Since, the CMP model is appeared to
be the best, we explain results from CMP model. From CMP model, although not
significant but β1 < 0 = 97.20%, the incidence rate of suffering from different sign
and symptoms of HIV patients who consumes multivitamin is lower [β1 =−0.09, 95%
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HPD: (− 0.17, 0.01), and the corresponding IRR= exp(−0.09/0.84)=0.91] than who
consumes placebo. The incidence rate of suffering from different sign and symptom
of HIV patients who consume multivitamin is lowed by 9% than those who consume
placebo while age and gender are adjusted.
For one month increase in the follow up time the incidence rate for sign and
symptoms decreases by 2 percent[β2 =−0.02, 95% HPD: (−0.03, −0.02), and the
corresponding IRR= exp(−0.02/0.84)=0.98] among the HIV patients, and statistically significant. The incidence rate ratio for signs and symptoms among male is
significantly lower than that of women [β4 =−0.22, 95% HPD: (−0.32, −0.12), and
corresponding IRR= exp(−0.22/0.84) = 0.77] while adjusting age, time and intervention.
The subgroup analysis illustrates that, male receiving multivitamin experience
lesser number of signs and symptoms (IRR=0.91), the experience is also in the similar
direction for female (IRR=0.90). As time goes up the male patients experience higher
reduction of symptoms (IRR=0.96) than that of the female patients (IRR=0.98).
Both in male and female groups, baseline age does not have significant role in reducing
sign and symptoms. We present posterior mean along with their corresponding 95%
HPD interval in Figure 4.1. It is observed that gender effect is significantly lower
than zero and treatment effect is marginally lower than zero, which illustrate that
male, and individuals in multivitamin group experience lesser number of sign and
symptoms respectively.

4.4

Discussion

Based on all model assessment criteria, our study reveals that the CMP model is an
ideal alternative to study, and identify the factors affecting the symptomology status
in HIV patients receiving multivitamin as a supplementary intervention. The CMP
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model has been proven as a better alternative to dispersed count data (K. F. Sellers
& Shmueli, 2010; Morris et al., 2017).
It is evident from all three models that multivitamin, time, and male gender have positive impacts in reducing the number of signs and symptoms. Limited
research has been conducted on the effect of multivitamin supplementation in HIV
patients. However, the roles of individual vitamins such as vitamin D and A have
been sufficiently studied in specific gender and comorbidity based sub-groups of HIV
infected population and such supplementation has been found to be beneficial. Multivitamin supplementation has been found to be associated with lower risk of death,
a higher CD4 count, lower viral loads, delayed disease progression, improved weight
gain and significant improvement in hematological status in pregnant females in Tanzania (Fawzi et al., 2004, 2007; Villamor et al., 2002). Similarly, among children,
probiotic and micronutrient supplementation has shown significant improvement in
CD4 count and delay in progression to advanced disease (Gautam et al., 2014). In
adult HIV infected population, multivitamin supplementation has shown a reduction
in oxidative stress (Allard et al., 1998). Individually, vitamin D deficiency has been
found to be associated with a higher all-cause mortality and AIDs event (Viard et
al., 2011), while its supplementation, and increase in serum concentration over time
is associated with a decrease in markers of T-cell activation, monocyte activation and
Interleukin-6 (an inflammatory biomarker) among adults (Benguella et al., 2018;
Eckard et al., 2018), and improved neuromuscular motor skills among children and
young adults (Brown et al., 2015). Majority of vitamin A supplementation studies
have been conducted in pregnant females and provide mixed results.
A systematic review of randomized control trials found no overall evidence of
a positive effect of intervention in mother to child transmission of disease, but they
did find significant positive effect on birth weight (Kongnyuy et al., 2009). Few
studies did not find any beneficial effects of vitamin supplementation (Guwatudde
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et al., 2015). We found that among males, the beneficial effects of multivitamin
supplementation were more evident as compared to females (as seen by the strength
of association). This is a novel finding to our knowledge as no previous interventional
study has assessed the role of gender. In this study, baseline age does not have any
significant association with sign and symptom.
This study has several strengths. The use of large double blind randomized
control trial data in HIV patients to study the effect of multivitamin is one of them.
Our results could be reliable because of large sample. Application of the Bayesian
CMP mixed effect model with higher order random effects to study longitudinal count
data as an alternative to other methods is another strength. However, this study is
not free from limitations. In our calculation, we observe that DIC, and WAIC for
NB model is substantially high in comparison to other models, seems to be counter
intuitive for over-dispersed data. Further investigation may be required. The model
could not adjust for other predictors especially certain comorbidities that could have
affected metabolism and mechanisms of actions of the vitamins as they were not
available from the original investigators. From this study, the sign of positive impact
of multivitamin supplementation in HIV patient’s health status would enhance the
application of multivitamin to the HIV patient population as a low cost therapy.
However, larger study may be conducted to produce generalizeable results.

4.5

CMP Model Implementation

No package supports mixed effect model when longitudinal count data distribution
is assumed as Conway Maxwell Poisson (CMP). We implement our analysis in R
environment with a R package rstan. It requires both Stan and R coding. We use
the matrix notation of mixed effect model of the form with the given notation in
Chapter 2
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log(θij ) = xTij β + z Tij ζ,

(4.2)

where ζ ∼ N (0, σζ2 ), and θij is the shape parameter of the CMP distribution associated with longitudinal count observation yij . CMP is not a default distribution
in Stan. Therefore, we had to adopt CMP distribution in Stan. The CMP model
implementation process are mentioned below step-wise (please follow the codes below
to match with steps):
1. Install the R package rstan with all its dependencies (R packages), and call
all required libraries.
# Library
library(rstan)
library(ggplot2)
2. Load data in R and generate a fixed effect design matrix. We can make a design
matrix for random effects too. However, we made here only design matrix for
fixed effects.
# Loading data assuming that data has trt,time,age,gender variables
data=read.csv("~data.csv")
#Design matrix for Fixed effects
X=(model.matrix(~1+trt+time+age+gender, data))
3. Express data as a list with the data to be used in the model, we call here it
standata.
# creating a list of data for

modeling in Rstan
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standata=list(Nobs=nrow(data),
Npreds = ncol(X),
Ngroups=length(unique(data$ID)),
y = data$countresponse,
X = X,
trt=data$trtment,
time=(data$visit_times),
group = as.integer(factor(data$ID)),
age=data$base_line_age)
4. Stan code can be written in two ways but we have to use one of them. Firstly:
write the Stan code in R environment with a name cmpcrs (say), all the Stan
code will be within inverted comma (‘. . . ’). Secondly: we can create a separate ‘∼ .stan’ file in notepad cmp.stan (say). Finally, call the code/file as
modelcode = cmpcrs or cmp.stan. However, here we apply first case as
cmpcrs = ‘.....’
5. Within Stan code user defined distribution’s loglikelihood can be developed.
In CMP distribution we have a normalizing constant which is an infinite sum,
we have to evaluate normalizing constant in 2 steps first with a main function.
Within the main function the function ‘ real Z (real theta, real phi) {...}’ evaluP
θik
ates the normalizing constant Z(θi , φ) = ∞
k=0 (k!)φ for subject i for θi and fixed
φ. The successive terms in the sum are diminishing and we included the term
in the sum until difference between two term is attained to < 0.0001

real Z(real theta, real phi){
real sm;
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real sm_prev;
int i;
real diff;
sm=0;
i=0;
diff=1;
while (diff > 0.0001){
sm_prev=sm;
sm=sm+exp(i*log(theta)-phi*lgamma(i+1));
diff=sm-sm_prev;
i=i+1;
}
return(sm);
return(i);
}

In the second step, we have to evaluate the vector Zv for all observations.
vector Zv(vector theta, real phi){
int N = rows(theta);
vector[N] zs;
for (i in 1:N){
zs[i] = Z(theta[i], phi);
}
return(zs);
Finally, the log-likelihood.
real compoisson_lpmf(int y, vector theta, real phi){
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int N = rows(y);
return-sum(log(Zv(theta,phi)))-phi*sum(lgamma(y+1)) + sum(y.*log(theta));
}
Note: For default distributions in Stan we do not require this step.
6. In data block define data including design matrix.
data {
int<lower=0> Nobs;

// number of observations

int<lower=0> Npreds;

// number of fixed effects

int<lower=0> Ngroups;
int y[Nobs];

// number of subjects
// response variable

matrix[Nobs,Npreds] X;
vector[Nobs] time;

// fixed effect design matrix
// measurement times or visit times

int<lower=1,upper=Ngroups> group[Nobs];

// group-wise observation

}
7. In parameter block define parameters of interest including regression coefficients, dispersion parameter, standard deviations of random effects that we
want to estimate. In this case to accommodate correlated random effects we
need to define Choleskey factor (L).
parameters {
real<lower=0.01> phi;

// dispersion parameter

vector[Npreds] beta;

// fixed effect regression coefficients

vector<lower=0>[2] sigma_zeta; //

variance of random effects

cholesky_factor_corr[2] L_zeta;
// L,Choleskey factor of correlation matrix
matrix[2,Ngroups] z_zeta;
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// matrix of randomly distributed random variables
}

8. In transform parameter block estimate theta from the proposed model, and
create correlated random effects by using




ζ01 ζ11 


ζ02 ζ12  
T



 = diag(σζ0 , σζ1 )Lζ z ζ
 ... ... 




ζ0I ζ1I
// transform parameter block
transformed parameters {
vector[Nobs] thetahat ; // vector of estimated theta
matrix[2,Ngroups] zeta; // matrix of random intercepts and slopes
zeta<-diag_pre_multiply(sigma_zeta,L_zeta)*z_zeta;
// creating correlated random-intercepts and slopes
// estimating thetas
for (i in 1:Nobs)
thetahat[i]<- exp(X[i]*beta+zeta[1,group[i]]+ zeta[2,group[i]]*time[i]);
}
9. In model block define priors of the parameters and generate posterior, here is
the end of Stan coding. we recommend uniform or normal priors for regression
parameters, uniform or inverse-gamma for variance parameter, log normal or
Halpf-Cauchy for dispersion parameter, LKJ with eta=2 or 1.5 for L
// model block
model {
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beta~ normal(0,10000);

// fixed effect regression coefficients

L_zeta~lkj_corr_cholesky(2.0);

// priors Choleskey factor

to_vector(z_zeta)~normal(0,1);

// prior for to-vector

phi~lognormal(0,15);

// prior for dispersion parameter

sigma_zeta~inv_gamma(0.1,0.1);

// prior for dispersion parameter

y ~ compoisson(thetahat, phi);
10. Now run the model with modelcode=cmpcrs and data= standata. Number
of chains and cores may be 1 or 2 or 3 or 4. Any number of thinning can
be used to avoid dependent samples for posterior properties calculations. One
can monitor progress of MCMC by using any number of refresh. The step
size, maximum number of tree depth, and metropolis acceptance ratio can be
controlled for better performance of MCMC samples. Default warm-up is 1/2
of the iterations. However, one can select any number of warm-ups.
# Rstan code for model running
fit.cmpcrs_mf=stan(model_code=cmpcrs, data= standata, iter = 5000,
chains = 4, cores=4, thin=1, refresh = 1000, init_r=0.01)
11. Print the output, one can specify parameters and 95% credible interval to
print. To monitor performance of MCMC trace plots, ACF plots, Pair plots
can also be produced.

//printing parameter estimates
print(fit.cmpcrs_mf, pars=c("phi","beta[1]",
"beta[2]", "beta[3]", "beta[4]","beta[5]",
’sigmaint’), probs=c(0.025,0.5,0.975))
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—————————————Full CMP Modeling code—————
Library
library(rstan)
library(ggplot2)
# Loading data assuming that data has trt,time,age,gender variables
data=read.csv("~data.csv")
//
#Design matrix for Fixed effects
X=(model.matrix(~1+trt+time+age+gender, data))
//
# Creating a list of data for Rstan modeling
standata=list(Nobs=nrow(data),
Npreds = ncol(X),
Ngroups=length(unique(data$ID)),
y = data$countresponse,
X = X,
trt=data$trtment,
time=(data$visit_times),
group = as.integer(factor(data$ID)),
age=data$base_line_age)
//
#start of STAN coding block for the correlated random intercept
#and slope with the name "cmpcrs"
cmpcrs = ’
#evaluate the normalizing constant (infinite sum)

functions{
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real Z(real theta, real phi){
real sm;
real sm_prev;
int i;
real diff;
sm=0;
i=0;
diff=1;
while (diff > 0.0001){
sm_prev=sm;
sm=sm+exp(i*log(theta)-phi*lgamma(i+1));
diff=sm-sm_prev;
i=i+1;
}
return(sm);
return(i);
}
vector Zv(vector theta, real phi){
int N = rows(theta);
vector[N] zs;
for (i in 1:N){
zs[i] = Z(theta[i], phi);
}
return(zs);
}
#define log likelihood
real compoisson_lpdf(vector y, vector theta, real phi){
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int N = rows(y);
return-sum(log(Zv(theta,phi)))-phi*sum(lgamma(y+1)) + sum(y.*log(theta));
}
}
#data block
data {
int<lower=0> Nobs;

// number of observations

int<lower=0> Npreds;

// number of fixed effects

int<lower=0> Ngroups;

// number of subjects

vector[Nobs] y;

// response variable

matrix[Nobs,Npreds] X;

// fixed effect design matrix

vector[Nobs] time;

// measurement times or visit times

int<lower=1,upper=Ngroups> group[Nobs];

// group-wise observation

}
#parameter block
parameters {
real<lower=0.01> phi;

// dispersion parameter

vector[Npreds] beta;

// fixed effect regression coefficients

vector<lower=0>[2] sigma_zeta;
cholesky_factor_corr[2] L_zeta;

//

variance of random effects

// L,Choleskey factor of correlation matrix

matrix[2,Ngroups]z_zeta;
// matrix of randomly distributed random variabl
//used to generate correlated random effects
}
#transform parameter block
transformed parameters {
vector[Nobs] thetahat ;
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// vector of estimated theta considered as parameters
matrix[2,Ngroups] zeta;

// matrix of random intercepts and slopes

zeta<-diag_pre_multiply(sqrt(sigma_zeta),L_zeta)*z_zeta;
// creating correlated random//-intercept and slope
# estimating thetas
for (i in 1:Nobs)
thetahat[i]<- exp(X[i]*beta+zeta[1,group[i]]+ zeta[2,group[i]]*time[i]);
}
# model block

model {
beta~ normal(0,10000);

// fixed effect regression coefficients

L_zeta~lkj_corr_cholesky(2.0);

// priors Choleskey factor

to_vector(z_zeta)~normal(0,1);

// prior for to-vector

phi~lognormal(0,15);
sigma_zeta~inv_gamma(0.1,0.1);

// prior for dispersion parameter
// prior for dispersion parameter

y ~ compoisson(thetahat, phi);
}’
#----- end of STAN coding block------# Rstan code for model running
fit.cmpcrs_mf=stan(model_code=cmpcrs, data= standata, iter = 5000, chains = 4,
cores=4, thin=1, refresh = 1000, init_r=0.01)
#Output posterior means with 95% Credible intervals
print(fit.cmpcrs_mf, pars=c("phi","beta[1]", "beta[2]", "beta[3]",
"beta[4]","beta[5]",
’sigmaint’), probs=c(0.025,0.5,0.975))
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Chapter 5
Conclusion and Future Research
Directions
Biomedical studies, clinical trials, and observational studies generate abundance of
count data. Often times, these data are measured longitudinally or cluster-wise.
McCullough & Nelder (1989) mentions that over-dispersion is a rule rather than
exception. Over-dispersion in the data arises for a variety of reasons. For instance,
when mean and variance are related in generalized linear models, due to important
predictor missing in the model, functional miss-specifications, correlation between
responses, excess variation in counts, and violation of distributional assumptions. On
the other hand under-dispersion is also arises when adjacent groups are correlated. It
can occur by data generating or modeling process, and usually seen in small sample
values. Failure to address over- and under-dispersion leads to bias inference and model
over-fitting respectively. Poisson model is a benchmark in count data analysis, and is
constrained by equi-dispersion assumption. Negative binomial model is dedicated to
deal with over-dispersion. Literature reveals that in terms of model fit and predictive
power, CMP model outperforms NB and Poisson as it can capture a wide spectrum
of dispersion in a parsimonious way (K. F. Sellers & Shmueli, 2010). In addition, the
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longer tail of the CMP distribution can capture extreme observations, and it enables
us to fit a single model instead of fitting separate models in different dispersion
conditions.
Besides, in modeling longitudinal count data, it is reasonable to think that
there is natural heterogeneity among the study subjects not only on their baseline
level but also in the change in the expected counts over time. In practice this situation
happens a lot. To address the heterogeneity and dispersion in count data we include
random effects in CMP regression model. The CMP model with subject-specific
random intercept and slope, and generalized additive mixed effect model with CMP
distributional assumption of count data were not studied in literature. Fitting such
models in the classical approach may be cumbersome due to complex nature of the
likelihood and integrational intractability. We propose a Bayesian approach for these
models and attempt to assess model performance based on the simulation and real
data analysis.
In Chapter 2, we fit a Bayesian generalized linear mixed effect model for longitudinal count data distributed as CMP by assuming a linear functional relationship
between expected mean counts and covariate effects. We fit CMP, Poisson, NB model,
and do model assessments by using LPML, LOO, WAIC, and DIC. From both simulated and real data analysis we experience that each of the model assessment criteria
does not perform equally in all situations, rather their performances are data specific.
The similar experience mentioned in Vehtari et al. (2017). Since we observe a consistent performance of DIC across dispersion conditions, we recommend to the use of
DIC for Bayesian model assessments, although it suffers from some limitations mentioned in Vehtari et al. (2017); Plummer (2008); Van Der Linde (2005). In simulated
study, based on DIC, we observed that CMP models fit better than other models. We
use epilepsy data to check performance of our proposed model. Epilepsy dataset is
well studied in literature. The data are over-dispersed, and no statistically significant
85

impact of study drug (progabide) was found in most of the analysis (Leppik et al.,
1987). Our proposed model also conforms similar findings.
In Chapter 3, we fit a Bayesian generalized additive mixed effect model for
longitudinal count data distributed as CMP by considering a non-linear functional
relation between expected mean counts and covariate effects. Such a model is widely
applicable in clinical trial data where functional relationship is not known in advance,
rather is data driven. We use an under-dispersed hypothetical dataset to fit the
proposed model. Our model could identify the under-dispersion in the data. Based
on all four model assessment criteria (LMPL, LOO, WAIC, and DIC) the CMP model
fits the best among others.
Whether the multivitamin supplementation is beneficial to explain symptomology in HIV patients receiving highly active antiretroviral therapy? By using CMP
model, Chapter 4 deals with the above research question. We found, the CMP model
fits the best, and model convergence is quite satisfactory. The model depicts that
the incidence rate of suffering from different sign and symptom of HIV patients who
consume multivitamin is lowed by 9% than those who consume placebo while age and
gender are adjusted.
In this study we encounter some problems and could not explain the reason
why they are arising, require further investigation. Some of the issues are: (1) although we do not encounter any problem in CPOs for simulated data, we experience
some subjects retain abnormally high values of CPO for epilepsy data, and makes
LPML questionable (2) in calculation of WAIC, variance of log posterior likelihood
across simulations produce high values (when exceeds 0.04 are not reliable) and makes
WAIC calculation unreliable for the real data (3) in Chapter 4 for a over-dispersed
multivitamin dataset, DIC for NB model is substantially high in comparing to the
other model.
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Our proposed models, Bayesian generalized mixed effect model with higher
order random effects, and Bayesian generalized additive mixed effect model are the
extensions to the existing literature for longitudinal count data modeling. The CMP
model saves us from model misspecification for count data. Due to unavailability of
ready to use software, the application of the CMP model is limited, despite having the
appealing properties of CMP distribution. We provide a tutorial for implementing
ting CMP model in STAN and Rstan, and attach full code in Appendix. We hope,
with the advent of computational procedure, the proposed model is easily extendable
to study subject and cluster specific variability in multi-site clinical trials by adding
cluster or site specific random effects in the model. While dealing with dispersed
longitudinal count responses, our proposed models can account for both linear and
non-linear relationship between expected counts and covariates arises from various
biomedical, public health, and business research.
Some noted future research plans are:
1. Developing CPO using weight function and corresponding logarithm of pseudo
marginal ikelihood (LMPL) as the Bayesian model assessment criteria with
Conway-Maxwell Poisson distributional assumption for longitudinal count data.
In Chapter 2, we used numerical calculation of CPO and LPML by using MCMC
samples based on CPO identity-I described in (Zhang et al., 2017). However,
we realized that CPO identity-II proposed in Zhang et al. (2017) remains unexplored in the context of CMP. CPO identity-II involves calculation of normalized weight function by using random effects, and approximation of covariance
matrix of random effects which remains for further study.
2. Exploring posterior identifiability condition under non-informative priors on
regression parameters (βk ) to develop a theoretical background. This involves
advance inequality techniques along with matrix rank calculation, to be explored
in future.
87

3. In dealing with Bayesian mixed effect model and GAM in Chapter 2 and Chapter 3 respectively, we did not deal with zero inflated and missing longitudinal
counts, and duel links (modeling log link of both shape and dispersion parameter), and automated knot selection in CMP setting which remain for further
extension.
4. Developing statistical joint model of time to event and longitudinal count data
distributed as Conway-Maxwell Poisson and its application in drug development.
There is a growing interest in statistical joint modeling in drug and medical
instrument development industry. Literature reveals that joint model provides
better insight for biomarkers and survival events, produce less bias, provides
greater efficiency by lowering sample size in the drug development process
(Lawrence Gould et al., 2015). A joint model includes a longitudinal model to
deal with bio-marker (may be dispersed counts) trajectory and survival model
to deal with time to events. However, research scope remains open in both
components.
5. Methodology development to identify the distribution and shape of the longitudinal data.
In practice, if longitudinal data is continuous, we assume normal distribution of
the data, for continuous rates/ratios/proportion we consider beta distribution,
categorical (binary, multinomial, ordinal) are dealt with binomial, multinomial
distribution, and count data with Poisson, negative binomial, CMP distribution,
etc;. But, rarely we pay attention to the shape of the distribution of the data. If
we want to see the shape of the longitudinal data, how can we do that? Should
we aggregate all data and plot them? Or should we plot data at each visit time
and address them with some mixture distribution? This option may be feasible
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for fixed time visits for patients, what about for continuous varying time points
(different visit times for different patients)? May need attention.
6. In case of joint modeling with multiple bio-markers, there is scope for methodology development when multiple bio-markers are measured in different time
points from the same subject.
7. Exploring both methodology and applied research windows relating to CMP
model in Biomedical and Public Health Research.
Use of CMP distribution is gaining popularity in biomedical and public health
research in recent years. For example, some of the studies are: study of proportional hazard and proportional odds under CMP cure rate model (Balakrishnan
et al., 2017; Balakrishnan & Feng, 2018; Pal et al., 2018), interval censored cure
rate (Wiangnak & Pal, 2018), cure rate model computation (He & Emura,
2019), study of dispersion in positron emission therapy (Santarelli et al., 2016),
modeling doctor’s visit using right censored zero-inflated CMP (Saffari et al.,
2018), modeling motor vehicle crash frequency (Abdella et al., 2019), zero inflated number of dental caries (Choo-Wosoba et al., 2016), to study fertility
count data (Peluso et al., 2019), accident prediction in highway crossing (Lu &
Tolliver, 2016), Weibull CMP to study survival data (Gupta & Huang, 2017), to
model number of babies born alive in multiple pregnancy (Erkan et al., 2017),
to study highway rail grade traffic hazard, to study annual reproduction rate.
The above studies may be helpful to unveil potential research scopes, mostly in
survival analysis and traffic safety studies.
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Appendix A

This appendix includes full conditional for BGMM
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Appendix B

Table B.1: 95% Credible Interval from simulated Under-dispersed (φ = 2.50) data
Model
CMP

NB

Poisson

Param

True

Mean

95%Crl.

HPD

φ

2.50

2.82

(1.89, 3.87)

(2.79, 3.87)

β0

−0.80

−.87

(−1.31, −0.45)

(−1.30, −0.4)

β1

−0.05

0.03

(−0.33,0.39)

(−0.33,0.39)

β2

−0.01

0.01

(−0.42,0.45)

(−0.42,0.45)

σ0

0.05

0.13

(0.01,0.48)

(0.00,0.41)

σ1

0.02

0.14

(0.01,0.52)

(0.00,0.44)

ρ

−0.50

−0.02

(−0.83,0.80)

(−0.84,0.78)

φ

-

0.04

(-)

(-)

β0

−0.80

−1.12

(−1.50,−0.76)

(−1.49,−0.75)

β1

−0.05

0.02

(−0.29,0.33)

(−0.29,0.33)

β2

−0.01

0.02

(−0.36,0.41)

(−0.36,0.40)

σ0

0.06

0.07

(0.01,0.26)

(0.00,0.22)

σ1

0.02

0.08

(0.01,0.29)

(0.00,0.25)

ρ

−0.50

−0.04

(−0.83,0.80)

(−0.85,0.77)

β0

−0.80

−1.11

(−1.50,−0.77)

(−1.48,−0.76)

β1

−0.05

0.02

(−0.35,0.40)

(−0.36,0.40)

β2

−0.01

0.02

(−0.35,0.40)

(−0.36,0.40)

σ0

0.05

0.07

(0.01,0.27)

(0.00,0.24)

σ1

0.02

0.07

(0.01,0.30)

(0.00,0.24)

ρ

−0.50

−0.04

(−0.83,0.80)

(−0.85,0.78)
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Table B.2: 95% Credible Interval from simulated Over-dispersed φ = 0.30 data
Model
CMP

NB

Poisson

Param

True

Mean

95%Crl

HPD

φ

0.30

0.39

(0.10, 0.75)

(0.09, 0.71)

β0

−0.80

−0.83

(−1.12,−0.53)

(−1.13,−0.53)

β1

−0.05

−0.01

(−0.23,0.22)

(−0.23,0.22)

β2

−0.01

−0.02

(−0.28,0.25)

(−0.29,0.25)

σ0

0.05

0.16

(0.01,0.43)

(0.00,0.38)

σ1

0.02

0.17

(0.01,0.49)

(0.00,0.42)

ρ

−0.50

−0.17

(−0.89,0.75)

(−0.93,0.67)

φ

-

0.45

(0.01,0.12)

(0.01,0.09)

β0

−0.80

−0.58

(−0.92,−0.25)

(−0.91,−0.24)

β1

−0.05

−0.01

(−0.30,0.28)

(−0.29,0.28)

β2

−0.01

−0.02

(−0.36,0.32)

(−0.36,0.32)

σ0

0.05

0.22

(0.01,0.58)

(0.00,0.50)

σ1

0.02

0.23

(0.01,0.54)

(0.00,0.55)

ρ

−0.50

−0.18

(−0.89,0.75)

(−0.93,0.66)

β0

−0.80

−0.64

(−1.02,−0.32)

(−1.00,−0.30)

β1

−0.05

−0.01

(−0.28,0.27)

(−0.28,0.27)

β2

−0.01

0.00

(−0.32,0.39)

(−0.34,0.36)

σ0

0.05

0.40

(0.04,0.82)

(0.02,0.75)

σ1

0.02

0.41

(0.05,0.91)

(0.03,0.84)

ρ

−0.50

−0.33

(−0.91,0.65)

(−0.95,0.53)

Table B.3: 95% Credible Interval from simulated Equi-dispersed φ = 1.00 data
Model
CMP

NB

Poisson

Param

True

Mean

95%Crl

HPD

φ

1.0

1.23

(0.69,1.82)

(0.68,1.80)

β0

−0.80

−0.81

(−1.20,−0.44)

(−1.19,−0.44)

β1

−0.05

0.00

(−0.31,0.30)

(−0.30,0.31)

β2

−0.01

−0.04

(−0.40,0.33)

(−0.40,0.32)

σ0

0.05

0.23

(0.01,0.64)

(0.00,0.55)

σ1

0.02

0.25

(0.01,0.71)

(0.00,0.62)

ρ

−0.50

−0.18

(−0.90,0.74)

(−0.94,0.66)

φ

-

0.07

(0.01,0.25)

(0.01,0.21)

β0

−0.80

−0.85

(−1.20,−0.53)

(−1.19,−0.52)

β1

−0.05

−0.00

(−0.29,0.29)

(−0.29,0.29)

β2

−0.01

−0.05

(−0.39,0.31)

(−0.39,0.30)

σ0

0.06

0.18

(0.01,0.48)

(0.00,0.42)

σ1

0.02

0.20

(0.01,0.56)

(0.00,0.47)

ρ

−0.50

−0.16

(−0.89,0.75)

(−0.93,0.68)

β0

−0.80

−0.85

(−1.20,−0.53)

(−1.19,−0.53)

β1

−0.05

−0.00

(−0.29,0.29)

(−0.29,0.29)

β2

−0.01

−0.05

(−0.38,0.31)

(−0.39,0.30)

σ0

0.05

0.19

(0.01,0.51)

(0.00,0.44)

σ1

0.02

0.21

(0.01,0.56)

(0.00,0.49)

ρ

−0.50

−0.16

(−0.89,0.75)

(−0.93,0.68)
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Appendix C

Figure C.1: Boxplot for subject-wise CPO for CMP model with φ = 0.30
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Figure C.2: Boxplot for subject-wise CPO for CMP model with φ = 1.00
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Appendix D

This appendix includes full conditional for BGAMM
φ
ni 
I Y
Y
yij
1
× exp xTij β + z Tij γ + ζi
π(β|γ, ζ, φ, y) ∝
yij !
i=1 j=1
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×
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φ
ni 
I Y
Y
1
π(φ|β, γ, ζ, y) ∝
×
yij !
i=1 j=1
×

exp − 21 (

P∞

k=0

exp xTij β + z Tij γ + ζi
(k!)φ

log φ−µφ 2 
)
ψ

ψφ
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×

1
C

k !−1

Appendix E

#setwd("C:....")

setwd("C:/Users/Desktop/Simulation_dt_1.5_cont_woi")
rm(list=ls())
# -----------------------Library----------------------------------------#

library(compoisson)
library(ggplot2)
library(MASS)
library(StanHeaders)
library(rstan)
library(shapefiles)
library(BayesX)
library(dplyr)
library(tidyverse)
library(MCMCvis)
library(parallel)
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#--------------------------CMP longitudinal data simulation----------------#
#---coefficients-----b0=-0.80
b1=-0.05
b2= -0.01
#--------N=100 #number of subjects
J=5 # number of measurements

#-----Data generation-----id=rep(1:N, rep(J,N))
x<-rep(c(0,1),N)
x1=x[rep(1:N,rep(J,N))]
tm=c(0,1,2,3,4)
t<-rep(tm,N)
t1=ifelse(t>0,1,0)

#---correlated random effects simulation-------set.seed(123)
library(mvtnorm)
q = 0.05
r = -0.50
s = 0.02

cov <- matrix(c(q^2, r * q * s, r * q * s, s^2), nrow = 2,
byrow = TRUE)
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re <- rmvnorm(N, mean = c(0, 0), sigma = cov)
u1<-round(rep(re[,1], rep(J,N)),4)
u2<-round(rep(re[,2], rep(J,N)),4)

#---shape parameter estimation-------

theta<-cbind(exp(b1+u1+b2*x1+(b3+u2)*t1))

phi=1.5 # dispersion parameter

#View(cdata)

cmp.DIC=NB.DIC=pois.DIC=rep(NA,100)
cmp.loglik=NB.loglik=pois.loglik=rep(NA,100)
cmp.EP=NB.EP=pois.EP=rep(NA,100)
# Saving output
cmp.out=matrix(NA, nrow = 100,ncol = 63);
colnames(cmp.out)=c(’phi’, ’sdphi’, ’cbphi2.5’, ’cphi.5’, ’cphi97.5’,
’hphi95l’, ’hphi95u’, ’rphi’,

’esphi’,

’b0’,’ sdb0’, ’cb02.5’, ’cb0.5’, ’cb097.5’, ’hb095l’, ’hb095u’, ’rb0’, ’esb0’,
’b1’, ’sdb1’, ’cb12.5’, ’cb1.5’, ’cb197.5’, ’hb195l’, ’hb195u’, ’rb1’, ’esb1’,
’b2’, ’sdb2’, ’cb22.5’, ’cb2.5’, ’cb297.5’, ’hb295l’, ’hb295u’, ’rb2’, ’esb2’
’sigu0’, ’sdsigu0’, ’csigu02.5’, ’csigu0.5’, ’csigu097.5’, ’hsigu095l’,
’hsigu095u’, ’rsigu0’, ’essigu0’,
’sigu1’, ’sdsigu1’, ’csigu12.5’, ’csigu1.5’, ’csigu197.5’, ’hsigu195l’,
’hsigu195u’, ’rsigu1’, ’essigu1’,
’crr’, ’sdcrr’, ’ccrr2.5’, ’ccrr.5’, ’ccrr97.5’, ’hcrr95l’, ’hcrr95u’,
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’rcrr’,’escrr’)

NB.out=matrix(NA, nrow = 100,ncol = 63);
colnames(NB.out)=c(’phi’, ’sdphi’, ’cbphi2.5’, ’cphi.5’, ’cphi97.5’,
’hphi95l’, ’hphi95u’, ’rphi’,

’esphi’,

’b0’,’ sdb0’, ’cb02.5’, ’cb0.5’, ’cb097.5’, ’hb095l’, ’hb095u’, ’rb0’, ’esb0’,
’b1’, ’sdb1’, ’cb12.5’, ’cb1.5’, ’cb197.5’, ’hb195l’, ’hb195u’, ’rb1’, ’esb1’,
’b2’, ’sdb2’, ’cb22.5’, ’cb2.5’, ’cb297.5’, ’hb295l’, ’hb295u’, ’rb2’, ’esb2’,
’sigu0’, ’sdsigu0’, ’csigu02.5’, ’csigu0.5’, ’csigu097.5’, ’hsigu095l’,
’hsigu095u’, ’rsigu0’, ’essigu0’,
’sigu1’, ’sdsigu1’, ’csigu12.5’, ’csigu1.5’, ’csigu197.5’, ’hsigu195l’,
’hsigu195u’, ’rsigu1’, ’essigu1’,
’crr’, ’sdcrr’, ’ccrr2.5’, ’ccrr.5’, ’ccrr97.5’, ’hcrr95l’, ’hcrr95u’,
’rcrr’,’escrr’)

pois.out=matrix(NA, nrow = 100,ncol = 54);
colnames(pois.out)=c(’b0’,’ sdb0’, ’cb02.5’, ’cb0.5’, ’cb097.5’, ’hb095l’,
’hb095u’, ’rb0’,’esb0’,
’b1’, ’sdb1’, ’cb12.5’, ’cb1.5’, ’cb197.5’, ’hb195l’, ’hb195u’, ’rb1’, ’esb1’,
’b2’, ’sdb2’, ’cb22.5’, ’cb2.5’, ’cb297.5’, ’hb295l’, ’hb295u’, ’rb2’, ’esb2’,
’sigu0’, ’sdsigu0’, ’csigu02.5’, ’csigu0.5’, ’csigu097.5’, ’hsigu095l’,
’hsigu095u’, ’rsigu0’, ’essigu0’,
’sigu1’, ’sdsigu1’, ’csigu12.5’, ’csigu1.5’, ’csigu197.5’, ’hsigu195l’,
’hsigu195u’, ’rsigu1’, ’essigu1’,
’crr’, ’sdcrr’, ’ccrr2.5’, ’ccrr.5’, ’ccrr97.5’, ’hcrr95l’, ’hcrr95u’,
’rcrr’,’escrr’)
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#--------------------- Stan data preparation------------------------

m=5000
T=1

#thin

C=4 # of chain
k=(m*C/(2*T))

for (ir in 1: 100) {

y=rcom(N*J,theta,phi) # CMP response
mean(y)
var(y)
#-----Final data---------------------------

cdata<-data.frame(id,x1, t1, tm,t,u1,u2, y)

X<-(model.matrix(~1+x1+t1, cdata ))
standat <- list(N = nrow(cdata),
P = ncol(X),
J = length(unique(cdata$id)),
y = cdata$y,
X = X,
x1=(cdata$x1),
t=(cdata$t1),
d = as.integer(factor(cdata$id)))
standat
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#------------------------------------STAN code: CMP_U-------------

cat("----------------CMP model is running-----\n")
cmp = ’
functions{
real Z(real theta, real phi){
real sm;
real sm_prev;
int i;
real diff;
sm=0;
i=0;
diff=1;
while (diff > 0.0001){
sm_prev=sm;
sm=sm+exp(i*log(theta)-phi*lgamma(i+1));
diff=sm-sm_prev;
i=i+1;
}
return(sm);
return(i);
}
vector Zv(vector theta, real phi){
int N = rows(theta);
vector[N] zs;
for (i in 1:N){
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zs[i] = Z(theta[i], phi);
}
return(zs);
}
// define log likelihood
real compoisson_lpmf(int

y, vector theta, real phi){

int N = rows(y);
return-sum(log(Zv(theta,phi)))-phi*sum(lgamma(y+1)) + sum(y.*log(theta));
}
}

data {
int<lower=0> N;
int<lower=0> P;
int<lower=0> J;
int y[N];
matrix[N,P] X;
vector[N] t;
int<lower=1,upper=J>id[N];
}
parameters {
real<lower=0.01> phi;
vector[P] beta;
vector<lower=0>[2] sigma_u;
cholesky_factor_corr[2] L_u;
matrix[2,J] z_u;
}
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transformed parameters {
matrix[2,J] u;
u<-diag_pre_multiply(sigma_u,L_u)*z_u;
}
model {
vector[N] thetahat ;
beta~ normal(0,10000);
L_u~lkj_corr_cholesky(2.0);
to_vector(z_u)~normal(0,1);
phi~lognormal(0,15);
sigma_u~inv_gamma(0.1,0.1);

for (i in 1:N)
thetahat[i]<- exp(X[i]*beta+u[1,id[i]]+ u[2,id[i]]*t[i]);
y ~ compoisson(thetahat, phi);
}’

#---------------Stan Model fitting:CMP_U--------

fit.cmp_u=stan(model_code=cmp, data= standat,
iter = m, chains = C, cores=4, thin=T,
refresh = 1000,init_r=0.01)

#--------------HPD calulation: CMP_U----------mc<-as.matrix(fit.cmp_u)
mc<-data.frame(mc)
cm<-read.csv("C:/Users/morshed.alam/Desktop/mc.csv")
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cm <- mc%>% select(-contains("z"))
%>%select(-contains("L"))
%>%select(-contains("sigma"))
%>%select(-contains("l"))
cm<-data.frame(subset(cm,select=c("phi","beta.1.","beta.2.","beta.3.")),
select(cm,contains("u.1.")),
select(cm,contains("u.2.")),
select(cm,contains("sigma_u.1.")),
select(cm,contains("sigma_u.2.")))

#----------DIC calculation: CMP_U--------

y <-cdata$y
t<-cdata$t1
loglikc <- NULL

for (i in 1:k){
Betac <- cm[i,2:4]
uic <- rep(unlist(cm[i,5:104]), each=5)
usc <- rep(unlist(cm[i,105:204]), each=5)
phic <- cm[i,1]
lambdac <- exp(X%*%t(Betac) + uic+usc*t)
likc<- sum(com.log.density(y,lambdac,phic, log.z=NULL))
loglikc <- c(loglikc,likc)
}

mean_simc<-mean(loglikc)
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# mean parameter calculation
theta_hatc = as.matrix(apply(cm, 2, mean))
Beta_hatc <- theta_hatc[2:4,1]
phi_hatc<-theta_hatc[1]
ui_hatc<-rep(unlist(theta_hatc[5:104,1]), each=5)
us_hatc<-rep(unlist(theta_hatc[105:204,1]), each=5)
lambda_hatc <- exp(X%*%Beta_hatc+ui_hatc+us_hatc*t)
likc_hat<- sum(com.log.density(y,lambda_hatc,phi_hatc, log.z=NULL))
Pc<-2*(likc_hat-mean_simc)
cmp.loglik[ir]<-likc_hat
cmp.EP[ir]<-2*(likc_hat-mean_simc)
cmp.DIC[ir]<--2*(likc_hat-Pc)

cat("----------------NB model is running-----\n")
#----------------------------------------------

nb=’
data {
int<lower=0> N;
int<lower=0> P;
int<lower=0> J;
int y[N];
matrix[N,P] X;
vector[N] t;
int<lower=1,upper=J>id[N];
}
parameters {
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real<lower=0.01> phi;
vector[P] beta;
vector<lower=0>[2] sigma_u;
cholesky_factor_corr[2] L_u;
matrix[2,J] z_u;
}
transformed parameters {
vector[N] thetahat;
matrix[2,J]u;
u<-diag_pre_multiply(sigma_u,L_u)*z_u;
for (i in 1:N)
thetahat[i]<-(X[i]*beta+u[1,id[i]]+ u[2,id[i]]*t[i]);
}
model {

beta~normal(0,10000);
phi~lognormal(0,15);
L_u~lkj_corr_cholesky(2.0);
to_vector(z_u)~normal(0,1);
sigma_u~inv_gamma(0.1,0.1);
y ~ neg_binomial_2_log(thetahat, 1/phi);
}’

fit.nb_u=stan(model_code=nb, data= standat, iter = m, chains = C,
cores=4, thin=T, refresh = 1000, init_r=0.01)
#---------------------------------HPD calulation: NB_U-----------107

mn<-as.matrix(fit.nb_u)
mn<-data.frame(mn)
nm <- mn%>% select(-contains("z"))
%>%select(-contains("L"))
%>%select(-contains("sigma"))
%>%select(-contains("l"))
nm<-data.frame(subset(nm,select=c("phi","beta.1.","beta.2.","beta.3.")),
select(nm,contains("u.1.")),
select(nm,contains("u.2.")),select(nm,contains("sigma_u.1.")),
select(nm,contains("sigma_u.2.")))

#------DIC_NB-----------------#
y <-cdata$y
t<-cdata$t1
loglikn <- NULL
for (i in 1:k){
Betan <- nm[i,2:4]
uin <- rep(unlist(nm[i,5:104]), each=5)
usn <- rep(unlist(nm[i,105:204]), each=5)
phin <- nm[i,1]
lambdan <- exp(X%*%t(Betan) + uin+usn*t)
likn <- sum(y * log(phin*lambdan) - (y + 1/phin)*log(1+phin*lambdan) +
lgamma(y + 1/phin) - lgamma(1/phin) - lgamma(y+1))
loglikn <- c(loglikn,likn)
}
mean_simn<-mean(loglikn)
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# mean parameter calculation
theta_hatn = as.matrix(apply(nm, 2, mean))
Beta_hatn <- theta_hatn[2:4,1]
phi_hatn<-theta_hatn[1]
ui_hatn<-rep(unlist(theta_hatn[5:104,1]), each=5)
us_hatn<-rep(unlist(theta_hatn[105:204,1]), each=5)
lambda_hatn <- exp(X%*%Beta_hatn + ui_hatn+us_hatn*t)
likn_hat <- sum(y * log(phi_hatn*lambda_hatn) (y + 1/phi_hatn)*log(1+phi_hatn*lambda_hatn)
+lgamma(y + 1/phi_hatn) - lgamma(1/phi_hatn) - lgamma(y+1))
likn_hat
Pn<-2*(likn_hat-mean_simn)

DICn<--2*(likn_hat-Pn)

NB.loglik[ir]<-likn_hat

NB.EP[ir]<-2*(likn_hat-mean_simn)

NB.DIC[ir]<--2*(likn_hat-Pn)

cat("----------------Poisson model is running-----\n")
#----------------------------------------------------------------#
pos=’
data {
int<lower=0> N;
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int<lower=0> P;
int<lower=0> J;
int y[N];
matrix[N,P] X;
vector[N] t;
int<lower=1,upper=J>id[N];
}
parameters {
vector[P] beta;
vector<lower=0>[2] sigma_u;
cholesky_factor_corr[2] L_u;
matrix[2,J] z_u;
}
transformed parameters {
vector[N] thetahat;
matrix[2,J]u;
u<-diag_pre_multiply(sigma_u,L_u)*z_u;

for (i in 1:N)
thetahat[i]<- exp(X[i]*beta+u[1,id[i]]+ u[2,id[i]]*t[i]);
}

model {
beta~normal(0,10000);
L_u~lkj_corr_cholesky(2.0);
to_vector(z_u)~normal(0,1);
sigma_u~inv_gamma(0.01,0.01);
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y ~ poisson(thetahat);
}’

#---------------------- Stan Model fitting:Pos_U------------------

fit.pos_u=stan(model_code=pos, data= standat, iter = m, chains = C,
cores=4, thin=T, refresh = 1000,init_r=0.01)

#---------------------------------HPD calulation: NB_U-----------mp<-as.matrix(fit.pos_u)
mp<-data.frame(mp)
pm <- mp%>% select(-contains("z"))
%>%select(-contains("L"))
%>%select(-contains("sigma"))
%>%select(-contains("l"))

pm<-data.frame(subset(pm,select=c("beta.1.","beta.2.","beta.3.")),
select(pm,contains("u.1.")),
select(pm,contains("u.2.")),select(pm,contains("sigma_u.1.")),
select(pm,contains("sigma_u.2.")))

#----------------DIC Poisson--------------------------#
y <-cdata$y
t<-cdata$t1

# Calculation of mean loglikelihood from simulation
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loglikp <- NULL
for (i in 1:k){
Betap <- pm[i,1:3]
uip <- rep(unlist(pm[i,4:103]), each=5)
usp <- rep(unlist(pm[i,104:203]), each=5)
lambdap <- exp(X%*%t(Betap)+uip+usp*t)
likp <- sum(y * log(lambdap) - lambdap - lgamma(y+1))
loglikp <- c(loglikp,likp)
}

mean_simp<-mean(loglikp) #mean of the loglikehood for all simulation
# Calculation of posterior mean estimation and loglikelihood
theta_hatp = as.matrix(apply(pm, 2, mean))
Beta_hatp <- theta_hatp[1:3,1]
ui_hatp<-rep(unlist(theta_hatp[4:103,1]), each=5)
us_hatp<-rep(unlist(theta_hatp[104:203,1]), each=5)
lambda_hatp <- exp(X%*%Beta_hatp + ui_hatp+ us_hatp*t)
likp_hat <- sum(y * log(lambda_hatp) - lambda_hatp - lgamma(y+1))
likp_hat # loglikelihood at poterior mean

Pp<-2*(likp_hat-mean_simp) # number of effective parameters
pois.loglik[ir]<-likp_hat
pois.EP[ir]<-2*(likp_hat-mean_simp)
pois.DIC[ir]<--2*(likp_hat-Pp)

#--------Results need to save-----------------------#

112

#-----------------------CMP Model output--------------------#
M0=as.matrix(MCMCvis::MCMCsummary(fit.cmp_u,
params = c(’phi’,’beta’, ’sigma_u’,’L_u’),
probs = c(0.025, 0.5, 0.975),
round = 3))
M0=t(M0)
M1=as.matrix(MCMCvis::MCMCsummary(fit.cmp_u,
params = c(’phi’,’beta’, ’sigma_u’,’L_u’),
HPD = TRUE,
hpd_prob = 0.95,
round = 3))
M1=t(M1)

result_c<-c(M0[1,1],M0[2,1],M0[3,1],M0[4,1],M0[5,1],M1[3,1],M1[4,1],
M0[6,1],M0[7,1],M0[1,2],M0[2,2],M0[3,2],M0[4,2],M0[5,2],M1[3,2],M1[4,2],
M0[6,2],M0[7,2],M0[1,3],M0[2,3],M0[3,3],M0[4,3],M0[5,3],M1[3,3],M1[4,3],
M0[6,3],M0[7,3],M0[1,4],M0[2,4],M0[3,4],M0[4,4],M0[5,4],M1[3,4],M1[4,4],
M0[6,4],M0[7,4],M0[1,5],M0[2,5],M0[3,5],M0[4,5],M0[5,5],M1[3,5],M1[4,5],
M0[6,5],M0[7,5],M0[1,6],M0[2,6],M0[3,6],M0[4,6],M0[5,6],M1[3,6],M1[4,6],
M0[6,6],M0[7,6],M0[1,9],M0[2,9],M0[3,9],M0[4,9],M0[5,9],M1[3,9],M1[4,9],
M0[6,9],M0[7,9])
cmp.out[ir,]<-result_c

#-----------------------NB

Model output--------------------#

M0=as.matrix(MCMCvis::MCMCsummary(fit.nb_u,
params = c(’phi’,’beta’, ’sigma_u’,’L_u’),
probs = c(0.025, 0.5, 0.975),
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round = 3))

M0=t(M0)

M1=as.matrix(MCMCvis::MCMCsummary(fit.nb_u,
params = c(’phi’,’beta’, ’sigma_u’,’L_u’),
HPD = TRUE,
hpd_prob = 0.95,
round = 3))
M1=t(M1)

result_n<-c(M0[1,1],M0[2,1],M0[3,1],M0[4,1],M0[5,1],M1[3,1],M1[4,1],
M0[6,1],M0[7,1],M0[1,2],M0[2,2],M0[3,2],M0[4,2],M0[5,2],M1[3,2],M1[4,2],
M0[6,2],M0[7,2],M0[1,3],M0[2,3],M0[3,3],M0[4,3],M0[5,3],M1[3,3],M1[4,3],
M0[6,3],M0[7,3],M0[1,4],M0[2,4],M0[3,4],M0[4,4],M0[5,4],M1[3,4],M1[4,4],
M0[6,4],M0[7,4],M0[1,5],M0[2,5],M0[3,5],M0[4,5],M0[5,5],M1[3,5],M1[4,5],
M0[6,5],M0[7,5],M0[1,6],M0[2,6],M0[3,6],M0[4,6],M0[5,6],M1[3,6],M1[4,6],
M0[6,6],M0[7,6],M0[1,9],M0[2,9],M0[3,9],M0[4,9],M0[5,9],M1[3,9],M1[4,9],
M0[6,9],M0[7,9])
NB.out[ir,]<-result_n

#-----------------------Poisson

Model output--------------------#

M0=as.matrix(MCMCvis::MCMCsummary(fit.pos_u,
params = c(’beta’, ’sigma_u’,’L_u’),
probs = c(0.025, 0.5, 0.975),
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round = 3))
M0=t(M0)
M1=as.matrix(MCMCvis::MCMCsummary(fit.pos_u,
params = c(’beta’, ’sigma_u’,’L_u’),
HPD = TRUE,
hpd_prob = 0.95,
round = 3))

M1=t(M1)

result_p<-c(M0[1,1],M0[2,1],M0[3,1],M0[4,1],M0[5,1],M1[3,1],M1[4,1],
M0[6,1],M0[7,1],M0[1,2],M0[2,2],M0[3,2],M0[4,2],M0[5,2],M1[3,2],M1[4,2],
M0[6,2],M0[7,2],M0[1,3],M0[2,3],M0[3,3],M0[4,3],M0[5,3],M1[3,3],M1[4,3],
M0[6,3],M0[7,3],M0[1,4],M0[2,4],M0[3,4],M0[4,4],M0[5,4],M1[3,4],M1[4,4],
M0[6,4],M0[7,4],M0[1,5],M0[2,5],M0[3,5],M0[4,5],M0[5,5],M1[3,5],M1[4,5],
M0[6,5],M0[7,5],M0[1,8],M0[2,8],M0[3,8],M0[4,8],M0[5,8],M1[3,8],M1[4,8],
M0[6,8],M0[7,8])

pois.out[ir,]<-result_p

}
#------COMP output---------------------#
cmp.out1<-cbind(cmp.out,cmp.DIC,cmp.loglik,cmp.EP)

write.csv(cmp.out1,
file ="C:/Users/morshed.alam/Desktop
/Simulation_dt_1.5_cont_woi/cmp.out_dt_1.5_cont_woi_1_uni_bc.csv")
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#------NB output---------------------#
NB.out1<-cbind(NB.out,NB.DIC,NB.loglik,NB.EP)

write.csv(NB.out1,
file = "C:/Users/morshed.alam/Desktop
/Simulation_dt_1.5_cont_woi/NB.out_dt_1.5_cont_woi_1_uni_bc.csv")

#------Pois output---------------------#
pois.out1<-cbind(pois.out, pois.DIC, pois.loglik, pois.EP)

write.csv(pois.out1,
file= "C:/Users/morshed.alam/Desktop
/Simulation_dt_1.5_cont_woi/pois.out_dt_1.5_cont_woi_1_uni_bc.csv")

#----------------End-------------------#

116

Bibliography
Abdella, G. M., Kim, J., Al-Khalifa, K. N., & Hamouda, A. M. (2019). Penalized
conway-maxwell-poisson regression for modelling dispersed discrete data: The case
study of motor vehicle crash frequency. Safety Science, 120 , 157–163.
Akaikei, H. (1973). Information theory and an extension of maximum likelihood
principle. In Proc. 2nd int. symp. on information theory (pp. 267–281).
Allard, J. P., Aghdassi, E., Chau, J., Tam, C., Kovacs, C. M., Salit, I. E., & Walmsley,
S. L. (1998). Effects of vitamin e and c supplementation on oxidative stress and
viral load in hiv-infected subjects. Aids, 12 (13), 1653–1659.
Alvarez, I., Niemi, J., & Simpson, M. (2014). Bayesian inference for a covariance
matrix. arXiv preprint arXiv:1408.4050 .
Balakrishnan, N., Barui, S., & Milienos, F. (2017). Proportional hazards under
conway–maxwell-poisson cure rate model and associated inference. Statistical methods in medical research, 26 (5), 2055–2077.
Balakrishnan, N., & Feng, T. (2018). Proportional odds under conway-maxwellpoisson cure rate model and associated likelihood inference. Statistics, Optimization
& Information Computing, 6 (3), 305–334.
Barnard, J., McCulloch, R., & Meng, X.-L. (2000). Modeling covariance matrices
in terms of standard deviations and correlations, with application to shrinkage.
Statistica Sinica, 1281–1311.
Baum, M. K., Campa, A., Lai, S., Martinez, S. S., Tsalaile, L., Burns, P., . . . others
(2013). Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral-naive, hiv-infected adults in botswana: a randomized clinical
trial. Jama, 310 (20), 2154–2163.
Benguella, L., Arbault, A., Fillion, A., Blot, M., Piroth, C., Denimal, D., . . . others (2018). Vitamin d supplementation, bone turnover, and inflammation in hivinfected patients. Medecine et maladies infectieuses, 48 (7), 449–456.
Boatwright, P., Borle, S., & Kadane, J. B. (2003). A model of the joint distribution
of purchase quantity and timing. Journal of the American Statistical Association,
98 (463), 564–572.
117

Borle, S., Boatwright, P., & Kadane, J. B. (2006). The timing of bid placement and
extent of multiple bidding: An empirical investigation using ebay online auctions.
Statistical Science, 194–205.
Borle, S., Boatwright, P., Kadane, J. B., Nunes, J. C., & Galit, S. (2005). The effect
of product assortment changes on customer retention. Marketing science, 24 (4),
616–622.
Brown, J. C., Schall, J. I., Rutstein, R. M., Leonard, M. B., Zemel, B. S., & Stallings,
V. A. (2015). The impact of vitamin d3 supplementation on muscle function among
hiv-infected children and young adults: a randomized controlled trial. Journal of
musculoskeletal & neuronal interactions, 15 (2), 145.
Carpenter, B., Gelman, A., Hoffman, M. D., Lee, D., Goodrich, B., Betancourt, M.,
. . . Riddell, A. (2017). Stan: A probabilistic programming language. Journal of
statistical software, 76 (1).
Chanialidis, C., Evers, L., Neocleous, T., & Nobile, A. (2014). Retrospective sampling
in mcmc with an application to com-poisson regression. Stat, 3 (1), 273–290.
Chanialidis, C., Evers, L., Neocleous, T., & Nobile, A. (2018). Efficient bayesian
inference for com-poisson regression models. Statistics and computing, 28 (3), 595–
608.
Chen, M.-H., Shao, Q.-M., & Ibrahim, J. G. (2012). Monte carlo methods in bayesian
computation. Springer Science & Business Media.
Choo-Wosoba, H., & Datta, S. (2018). Analyzing clustered count data with a clusterspecific random effect zero-inflated conway–maxwell–poisson distribution. Journal
of applied statistics, 45 (5), 799–814.
Choo-Wosoba, H., Gaskins, J., Levy, S., & Datta, S. (2018). A bayesian approach for
analyzing zero-inflated clustered count data with dispersion. Statistics in medicine,
37 (5), 801–812.
Choo-Wosoba, H., Levy, S. M., & Datta, S. (2016). Marginal regression models for
clustered count data based on zero-inflated conway–maxwell–poisson distribution
with applications. Biometrics, 72 (2), 606–618.
Chu, C., & Selwyn, P. A. (2011). An epidemic in evolution: the need for new models
of hiv care in the chronic disease era. Journal of Urban Health, 88 (3), 556–566.
Consul, P. C., & Jain, G. C. (1973). A generalization of the poisson distribution.
Technometrics, 15 (4), 791–799.
Conway, R. W., & Maxwell, W. L. (1962). A queuing model with state dependent
service rates. Journal of Industrial Engineering, 12 (2), 132–136.

118

Daly, F., & Gaunt, R. E. (2015). The conway-maxwell-poisson distribution: distributional theory and approximation. arXiv preprint arXiv:1503.07012 .
Deeks, S. G., Lewin, S. R., & Havlir, D. V. (2013). The end of aids: Hiv infection as
a chronic disease. The Lancet, 382 (9903), 1525–1533.
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